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PHARMACOLOGY 
ABSTRACT  
 
 
Mercury accumulates in fish-eating populations. Glial cells have diverse functions including 
providing nutrition[1], maintaining CNS homeostasis, removing pathogens, inducing neuronal 
differentiation and mediating CNS immune responsiveness. Dysfunction of glial cells is 
contributed to MeHg-induced brain damage. We hypothesized that 1) the cellular responses to 
MeHg are cell-type specific; 2) differences exist in the uptake of MeHg between astrocytes and 
microglia, leading to differential temporal cellular responses. I tested the unique response of 
primary glial cells to MeHg exposure at physiologically relevant concentration. The results are 
presented in this dissertation.  
 
Firstly, I established the methodology to separate a large amount of rat primary microglial cells 
with high purity (>95%) from mixed glial cell culture. Secondly, I investigated the toxic effects of 
MeHg on primary glial cells as well as their cellular response to acute MeHg exposure at 
environmentally relevant concentrations (0.1µM~ 5µM). The results showed MeHg treatment 
caused a concentration- and time- dependent microglial cell death, intracellular ROS generation 
and GSH depletion. I analyzed the dynamic changes of nuclear factor erythroid- derived 2- like 2 
(NFE2L2) in both cytosolic fraction and nuclear fraction. My results suggested that the increase in 
Nrf2 protein level and the subsequent nuclear translocation are regulated by ROS in both glial cell 
types. However, Nrf2 changes in astrocytes occurred on a protracted time scale. Thirdly, the 
effects of Nrf2 on its downstream gene expression and cell viability post MeHg exposure were 
further studied, using short hairpin RNA (shRNA) approach. Finally the responses of rat primary 
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microglial cells post MeHg treatment were compared with those of rat primary astrocytes. In 
conclusion, our study has demonstrated that microglial cells are more sensitive than astrocytes to 
MeHg. Their regulation kinetics differ, therefore allowing astrocytes and microglial cells to play 
different roles in mediating MeHg toxicity.  
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CHAPTER I 
 
INTRODUCTION 
 
Heavy Metal Pollution 
Toxic heavy metals in air, soil and water are growing global threats to human beings. Heavy 
metal pollution comes from various sources, including coal, natural gas, chlor-alkali industries 
and volcanic eruptions [3], but the most common source arises from the purification of metals, 
e.g., the smelting of copper and the preparation of nuclear fuels [4]. Currently, the thirteen 
elements of highest concern worldwide are As, Cd, Co, Cr, Cu, Hg, Mn, Ni, Pb, Sn and Ti [4], of 
which the emission is tightly regulated in waste incinerators. Some of these heavy metals are 
actually essential for humans in minute amounts (Co, Cu, Cr, Mn and Ni), but others are highly 
toxic (e.g. Hg, Pb and As). Notably, different heavy metals have different target organs. For 
example, Hg, Mn and Pb mainly cause damage to the central nervous system (CNS), especially 
during developmental stages. Kidneys and livers are susceptible to Cr and Cu, while hard tissues 
such as bones and teeth are mainly affected by Ni, Cd and Pb.  
 
Once released into environment, heavy metal pollutants can localize and do not decay. As the 
result, their toxicity may last for generations. Coastal fish and seabirds are often monitored for 
the presence of heavy metal contamination based on the fact the accumulative capability of sea 
animals presents the major concern of bioaccumulation and biomagnification of several heavy 
metals that have been linked to human diseases. Among them, the most notorious one is 
Minamata disease caused by organic mercury, MeHg poisoning [5-7]. Besides Minamata disease 
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caused by organic mercury, other heavy metals also cause human diseases. For example, Cd 
poisoning in Toyama Prefecture, Japan in 1912 caused Itai- itai disease, which led to weak and 
brittle bones, spinal and leg pain and waddling gait [8, 9].  Lead (Pb) poisoning can cause a 
variety of symptoms and signs, depending on the individual and the duration of lead exposure, 
and individuals with elevated lead levels may exhibit no symptoms [10]. In general, the 
symptoms of heavy metal poisoning are different between inorganic and its organic forms. And 
symptoms appear in children at lower blood level than in adults [11].  
 
Mercury and MeHg Pollution 
There are multiple natural sources of mercury. For example, cinnabar ore has high concentration 
of mercury. Volcanic eruptions release large amount of mercury to environment, especially to 
water system. Once in the water system, bacteria in oceans convert inorganic mercury into the 
organic form, methylmercury (MeHg), which is the most prevalent and one of the most toxic 
forms. Human exposure to mercury is predominantly from the consumption of fish [12-14] and 
mainly in the form of MeHg. MeHg enrichment in the aquatic food chain is not uniform and is 
dependent upon water Hg content, bottom sediments, water pH and redox potential, the species, 
age and the size of a particular fish. The micro-environment conditions, especially anoxia, favors 
the growth of micro-organisms and further increases the methylation rate of Hg [15].  
 
Japan [5, 6] and Sweden [16] have reported catastrophic epidemics caused by environmental 
MeHg poisoning. Analogous to sensitivity to other heavy metal pollution, children are more 
vulnerable to MeHg toxicity and have been found to exhibit diskinesia and intellectual 
disturbances [17]. In the general population, symptoms of MeHg poisoning are clinically 
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significant once the Hg exposure level exceeds the U.S. EPA RfD of 0.1 µg/kg body weight/day. 
These symptoms include mental retardation, primitive reflexes, coordination disturbance, 
dysarthria, limb deformation, growth disorder, chorea-athetose and hypersalivation[18].  
 
Once in the human body, MeHg redistributed from gastrointestinal tract to almost all organ 
systems. Figure 1 summarizes the kinetics of MeHg distribution in the human body. As shown in 
Figure 1, MeHg derived from food or occupational exposure is efficiently absorbed (90%) and 
has a long retention time (half-life of ~70 days). After ingestion, the distribution to the blood 
compartment is complete within 30 hours, and the blood level accounts for about 7% of the 
ingested dose [19]. Circulating MeHg accumulates predominantly in red cells where it binds to 
cysteinyl residues (-SH) on the hemoglobin beta-chain [20], and is then slowly distributed, 
reaching an equilibrium with other tissues at ~4 days [19].  
 
The MeHg concentration in blood and hair reflects the body burden, with a blood/hair 
concentration in humans approximating 1/250 under steady-state conditions [21]. The net 
mercury excretion rate in humans is approximately 1% of the body content at non-symptomatic 
body burden level [22]. Most of the MeHg is eliminated through the liver into the bile and 
through the kidney into the urine. But most MeHg undergoes enterohepatic circulation by 
reabsorption from the bile in the gut. Slower urine excretion of MeHg in female versus male rats 
has been reported to result in higher toxicity in female rats [23]. Diet can affect the MeHg 
excretion rate, since certain dietary components can interfere with MeHg reabsorption in the 
lower part of the intestines, thus breaking up the enterohepatic circulation [24]. 
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Fig 1 
  
Fig 1. The distribution of MeHg in the human body. MeHg is readily absorbed by the lung, skin 
and gastrointestinal tract. Once in the circulation, MeHg predominantly accumulates in red blood 
cells and is slowly re-distributed to other organ systems, including the CNS (major), kidneys and 
liver. MeHg can cross the placental-blood barrier and it accumulates in the fetus at a higher 
concentrations compared to the mother. (Mingwei Ni, et al. Chapter 35, Mercury, Reproductive 
and Developmental Toxicology, 2011)  
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Notably, MeHg can cross the placenta and accumulate in the fetus at concentration higher than 
that in the mother. For example, MeHg level in the neonatal cord blood is more than twice as 
high as that in maternal blood at delivery. And approximately 5% of the total MeHg in the 
maternal blood is found in breast milk [25]. However, infant blood MeHg level decreases 
significantly during the first 13 weeks of the infant’s life, and, at three months, maternal MeHg 
concentrations are higher than those of the infant, in contrast to those seen at parturition [26]. 
The rapid decline in infant MeHg concentrations postpartum can be explained by lower mercury 
transfer through breast milk and rapid infant growth after birth [26]. Furthermore, the systems for 
excretion develop as the children mature. For example, in experiment feeding young chickens 
with mercury contained water, the authors found an increase in relative kidney weight, which 
could indicate the increase in the excretion capability [27]. Mercury exposure also increases the 
urinary flow rate, which is suggested by the increase in the creatinine excretion rate in children 
[28].     
 
The mechanism of MeHg uptake has been extensively investigated and it has been shown that 
MeHg has a remarkably high affinity for the anionic form of –SH groups [29] and subsequently, 
MeHg form a complex with the –SH containing amino acid cysteine [30]. The MeHg-SH bond is 
highly thermodynamically stable, but the very rapid exchange of MeHg between –SH groups is 
known to occur [31]. Our laboratory has successfully shown that the MeHg-S-Cys complex 
closely mimics the structure of the neutral amino acid, methionine, and is therefore is a substrate 
of the L type large neutral amino acid transporter system (LAT1) [32]. Over-expression of LAT1 
in CHO-k1 cells is associated with enhanced uptake of [14C]-MeHg when the cells are treated 
with L-cysteine. On the other hand, L-methionine, the substrate for LAT1, significantly 
 6 
 
decreases the uptake of L-cysteine-conjugated [14C]-MeHg [32]. Kajiwara [33] also reported that 
MeHg crosses the placenta via a similar neutral amino acid carrier, accumulating in fetal blood in 
a time- and dose-dependent manner.  
 
Glial Cells  
I. Astrocytes  
Astrocytes, also known as astroglia, are characteristic star shaped glial cells in the brain and 
spinal cord. Astrocytes carry out many important functions to maintain CNS homeostasis, 
including supporting endothelial cells, participating in the formation of blood-brain barrier 
(BBB), providing nutrients to neuronal cells, playing principle role in the repair of brain and 
spinal cord after trauma. Astrocytes can be easily identified by glial fibrillary acidic protein 
(GFAP) staining. Histologically, astrocytes can be classified as three major types: fibrous, 
protoplasmic and radial glial cells. Fibrous glial cells have vascular feet, the long unbranched 
celluluar processes, wrapping the capillary wall. Protoplasmic glia are mainly found in grey 
matter tissue with large amount of intracellular organelles and this type of glial cells have short 
highly branched processes, which participating in the maintenance of extracellular ion balance. 
Radial glial cells are mostly present during development and guarding the developing neuron 
migration.  Pathologically, astrocytes are the major cell type in the scarring process of CNS after 
traumatic injury, infection and inflammation. Astrocytes also have many more functions 
including 1) glutamate uptake; For example, Bechtholt-Gompf [34] reported that the blockage of 
the central astrocytic glutamate uptake with the astrocytic glutamate transporter (GLT-1) 
inhibitor, dihydrokainic acid (DHK), induces signs of anhedonia and impaired spatial memory. 
2) astrocytes also function as the doorkeepers of GABA receptor functions; Beenhakker and his 
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colleagues [35] reported that astrocytic GABA transporters, GAT1 and GAT3 have different 
regulatory functions of GABA-mediated inhibitory postsynaptic currents (IPSCs), which are 
critical for the generation of generalized thalamocortical seizures.  They further discovered that 
the perisynaptic expression of GAT1 enables it to regulate GABA levels near synapses and 
selectively modulate peak IPSC amplitude, which is largely dependent on perisynaptic receptor 
occupancy. GAT3 expression, on the other hand, is broader and includes distal extrasynaptic 
regions.  3) Astrocytes also participate in potassium (K+) spatial buffering; 
The depolarization of neurons tends to raise potassium concentration in the extracellular fluid. If 
a significant rise occurs, it will interfere with neuronal signaling by depolarizing neurons. 
Astrocytes have large numbers of potassium ion channels facilitating removal of potassium ions 
from the extracellular fluid and the uptaken potassium are then distributed to its neighbors 
via gap junctions. This keeps extracellular potassium at levels that prevent interference with 
normal propagation of an action potential [36]. 4) astrocytes are also involved in the control pH. 
Carbonic anhydrase is found to be located in astrocytes at the blood brain barrier [37, 38], 
involving the transport of HCO3- linked to the acceleration of intra-astrocytic CO2 hydration. 
Subsequent studies also showed Na+/H+ and Cl-/HCO3- exchangers in primary astrocyte culture 
[39].  
 
II. Microglia 
Mcroglia are the resident macrophages of brain and spinal cord, acting as the main form of active 
immune defense in CNS. Microglia are distributed in large non-overlapping regions throughout 
the CNS and they are constantly excavating the CNS for damaged neurons, plaques and 
infectious agents. Microglia recognize foreign bodies and act as antigen-presenting cells 
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activating T helper cells. Since this unique proper of microglia, microglia are extremely sensitive 
to even small pathological changes in CNS to prevent potentially fatal damage happening [40]. 
Microglia have multiple functions, including scavenging and phagocytosis: each microglial cell 
surveys its own domain on a regular basis and it will be activated and phagocytose any foreign 
material, damages cells, apoptotic cells, DNA fragments or plagues. Thus, microglial cells act as 
“housekeeping” cells in CNS [41]. In addition to destroying infectious organisms through direct 
cell-to-cell contact via phagocytosis, microglia are also able to release numerous cytotoxic 
substrances. For example, Zhang [42] reported that cultured microglia secrete large amount of 
hydrogen peroxide. Ryu further [43] reported that activated microglia release NO after thrombin 
treatment via protein kinase C, mitogen-activated protein kinase and NF-κB signal pathway.  
Both these chemicals can directly damage cells and lead to neuronal cell death. Microglial cells 
also participate in the formation of complex extracellular signaling system which allows them to 
communicate with other cell types in the CNS including astrocytes, neurons, T cells and 
oligodentratic cells. For example, microglial cells release INF-γ into the extracellular space, 
which activates more microglial cells and astrocytes. Microglia also release TNF-α causing 
neuronal apoptosis and increasing inflammation. Another cytokine, IL-8, promotes B cells 
differentiation allowing it to assist microglia in cleaning infections. Additional dendritic cells 
and T cells are further recruited to the injured site via IL-8. Microglial activation leads to 
neuronal damage via NMDA receptor- mediated processes by secreting glutamate and aspartate. 
Takeuchi [44] reported that microglia have high concentration of glutaminase, which generates 
glutamate. When glutaminase was inhibited in vitro by adding glutamase inhibitor, 6-diazo-5-
oxo-l-norleucine (DON), to cultured microglia, the ability of the activated microglia to make 
glutamate and subsequently to kill neurons was decreased. It is noteworthy that the blockage of 
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glutamate receptor has been proven to have therapeutic functions. For example, Riluzole, the 
first drug approved for treatment of amyotrophic lateral sclerosis (ALS) works in part through 
suppressing the interaction of glumate with its receptor, as well as upregulating activity of 
glutamate transporters that clear glutamate.  Furthermore, Riluzole has actually been 
demonstrated to inhibit MS-like disease in the EAE (experimental allergic encephalomyelitis) 
model [45].   
 
Pathologically, microglia play critical role in neuroinflammation by expanding the 
neurodestructive effects via releasing cytokines (IL-1α, IL-1β and TNF-α), chemokines 
(monocyte chemoattractant protein-1, chemokine C-C motif receptor3, 5 and fractalkine 
receptor), release of proteases (cathepsins B, L, and S, the matrix metalloproteinases MMP-1, 
MMP-2, MMP-3, and MMP-9). Microglia are also involved in numerous neurodegenerative 
diseases, such as Alzheimer’s disease, Parkinson’s disease, HIV- associated dementia and etc. 
For example, in brain samples of Alzheimer’s disease patient, microglia are often found near 
damaged tissue and previous studies revealed that microglia play opposing roles in Alzheimer’s 
disease pathogenesis: on one hand, they eliminate β-amyloid aggregates via phagocytosis, on the 
other hand, they also kill nearby neurons by causing inflammation and the release of neurotoxic 
proteases.[46-48]. Microglia also play a significant role in dopaminergic cell injury. Le [49] 
developed an in vitro model of nigral injury, in which lipopolysaccharide (LPS)- induced 
microglial activation leads to injury of a dopaminergic cell line and dopaminergic neurons in 
primary messencephalic cell cultures. Microglia are also activated in Parkinson’s disease IgGs in 
the presence of low-dose dopa-quinone- or H2O2-modified dopaminergic cell membranes but not 
cholinergic cell membrane. Furthermore, this activation requires the microglial FcγR receptor as 
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demonstrated by the lack of activation with PD IgG Fab fragments or microglia from FcγR−/− 
mice. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system 
(CNS) can result in neurological dysfunction with devastating consequences. Interestingly, HIV-
1 does not infect neurons directly but induces damage indirectly through the accumulation of 
activated microglia. The infected microglia release neurotoxic mediators including both cellular 
activation products and viral proteins [50]. These viral proteins and cellular products have 
neurotoxic properties as well, both directly and through induction of astrocyte dysfunction, 
which ultimately lead to neuronal injury and death [50].  
 
On the other hand, microglia also play critical role in the neuroprotection. For example,  in 
vertebrates, several lines of evidence demonstrate that microglia are also involved in 
neuroprotection by t\secretiing IL-4 which triggers neural repair and contributes to the creation 
of an environment conductive for regeneration. Microglial IL-4 also induces neurogenesis and 
oligodendrogenesis in vitro [51]. In addition, microglia are principally the first cell type engaged 
in phagocytosis, removing neuronal debris [51]. Given the complexity of microglial functions, 
further studies are warranted to better understand their role in CNS diseases and repair processes.  
 
MeHg-induced Brain Injury  
MeHg caused brain injury is pathologically characterized by atrophy of cerebral cortex and white 
matter [52]. Eto further reported the thinning of the corpus callosum [53]. Microscopically, 
calcarine, postcentral and precentral cortices of cerebrum were found to be atrophic with a 
slightly decreased number of neurons and gliosis[53]. Calcification can also be detected in the 
globus pallidus. In the basal ganglia, there is loss in neurons. Interestingly, ventral nerve roots of 
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the spinal cord generally remain intact, but the connective tissue is increased. Furthermore, 
segmental demyelination in the dorsal nerve fibers is also observed [53]. Electron microscopy of 
human autopsy specimen clearly shows that nerve cells are shrunken with an increase in nuclear 
chromatin. Ribosome aggregation and loss of rough endoplasmic reticula (Nissl bodies) are also 
noted [52],  
 
MeHg causes severe brain injury, which is reflected by behavior changes in both human beings 
and animals. Among all neurodeficits, the motor impairment is an important behavioral sign 
observed in MeHg-poisoned animals,  Kitamura[54] reported that cats fed a diet that primarily 
consisted of fish in Minamata district presented a severe movement disorders, convulsions and 
death. Takeuchi [55] also reported that fish-feeding cats that lived on Indian Reserves in 
Northwestern Ontario, Canada, developed acute neurological symptoms characterized by ataxic 
gait, abnormal movements, uncontrolled howling, and seizures. Similar symptoms have been 
observed in numerous experimental animals including dogs [56], mice [57, 58]; rats [59, 60], 
monkeys [61] and zebrafish (Danio rerio) [62]. Notably, other CNS symptoms such as visual 
dysfunction (measured by visual contrast sensitivity task) [63], cognitive impairment (tested by 
passive avoidance task) [64] and emotional dysfunction (depression-like behavior evaluated in 
the forced swimming test) [65] have also been reported.  
 
The neurotoxicity of MeHg is also dependent on the stage of development. Compared to the 
adult CNS, the developing CNS is more susceptible to MeHg [66]. Mansour [67] showed that 
MeHg is transferred across the placenta from pregnant rats to their fetuses. Olson [68] further 
conducted a study on the pharmacokinetics of MeHg using murine maternal-fetal unit which 
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showed that the fetal accumulation of mercury increased with fetal age and peak fetal mercury 
was reached 3 days post MeHg administration. Another interesting experimental study using 
pregnant mice showed significant changes in biochemical parameters in the fetuses’ brain and 
absent changes in the mothers’ brain [69], which suggested that the transfer of MeHg from the 
pregnant animals to their fetuses via the placenta led to neurotoxicity in the offspring with no 
evident neurotoxic signs in their respective mothers. Interestingly, epidemiological studies 
corroborated this observation in humans as well [70]. Taken together, all the literatures support 
the notion that the developing CNS is most susceptible to the deleterious effects of MeHg than 
adult CNS. 
 
Toxicity of MeHg in Neurons 
The neuron is the primary target for MeHg [71], but the vulnerability of neurons decreases as the 
CNS matures [72, 73]. In general, MeHg poisoning results in focal damage in adults and 
widespread and diffuse damage in the fetal and neonatal brain [74]. In adult patient, the brain 
areas most vulnerable to MeHg include the primary sensory and motor cortices, pre- and post-
central gyri, the temporal transverse gyrus and the cerebellum (but not Purkinje cells) [75]. In 
contrast, congenital exposure to MeHg leads to widespread neuron injury. Pathologically, it 
results in cortical atrophy, thinning of the corpus collosum, white matter shrinkage and diffuse 
spongiosus [75, 76]. 
 
The mechanisms of MeHg-induced neuronal death have been studied in the past decades, which 
points to several critical features, namely: 1) inhibition of neuronal macromolecule synthesis 
(DNA, RNA and protein); The binding of MeHg with neuronal DNA and RNA results in 
 13 
 
changes in the secondary structure of these molecules [77, 78]. Furthermore, MeHg inhibits 
DNA repair by directly binding to the “zinc finger” core of DNA repair enzymes, deforming the 
structural integrity and activity of these enzymes and consequently affecting their activity [79]. 
2) MeHg disrupts microtubules; Sager [80] reported that MeHg inhibits the polymerization of 
tubulin. Castoldi [81] reported that MeHg at concentration of 0.5–1 µM leads to microtubular 
fragmentation formation in cultured primary rat cerebellar granular neurons. Given the fact that 
microtubules participate in cell division, their fragmentation by MeHg results in antimitotic 
effects, as well as the inhibition of neuronal migration and the degeneration of neuritis [82]. 
Furthermore, Leong [83] reported that mercury inhibits tubulin polymerization into microtubules 
using large pedal A (PeA) neurons from the central ring ganglia of snails. The 
tubulin/microtubule structure of growth cones was found to be disintegrated after mercury 
exposure using immunohistochemistry. He demonstrated that mercury markedly disrupted 
membrane structure and linear growth rates of neurites in 77% of all nerve growth cones [83]. 
Interestingly, Vendrell [84] proposed that mercury may affect neuronal polarity formation. She 
reported methylmercury disrupts the balance between phosphorylated and non-phosphorylated 
cofilin in primary mice cerebellar granule cells culture using  MALDI-TOF PMF and MALDI-
TOF/TOF sequencing. As the result of the disruption of cofilin phosphorylation, the actin 
dynamics were changed, which may disrupt cellular polarity formation [84]. However, more 
studies are warranted in order to fully understand the effects of mercury on neuronal polarity 
change. 3) MeHg leads to an increase in intracellular Ca2+; MeHg increases Na2+ and 
decreases K+ ion concentration in synaptic spaces, which leads to increased intracellular Ca2+ 
concentration [85, 86]. Ca2+ is the key molecule in the regulating neurotransmitter release and 
the change in intracellular Ca2+  leads to the disruption of cell signaling cascade. For example, 
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the increased release of dopamine, glutamate, -amino butyric acid (GABA), glycine, choline 
[87] and acetylcholine [88] have been reported. Furthermore, the inhibition of the uptake of 
glutamate and aspartate, has also been implicated as a major mechanism of MeHg-induced 
neurotoxicity [89, 90]. 4) MeHg alters neuronal energy metabolism; MeHg stimulates the 
ubiquinol: cytochrome C reductase complex (complex III) on the mitochondrial membrane [91], 
while inhibiting glutathione peroxidase (GPx) [92], which leads to lipid peroxidation. MeHg also 
inhibits tri-carboxylic-acid (TCA) cycle activity and decreasing ATP utilization in neurons [93, 
94]. Since the neuron is strictly dependent upon glucose for its energy production, high oxygen 
utilization and excitability renders it especially susceptible to MeHg; and 5) MeHg causes 
oxidative stress in neurons. MeHg is known to induce oxidative stress both in vitro and in vivo 
[95-97]. The production of ROS by MeHg exacerbates toxicity by facilitating cell death via 
apoptotic pathways. Inhibition of glutathione peroxidase (GPx) by MeHg further potentiates lipid 
peroxidation. Conversely, several studies have demonstrated partial amelioration of MeHg 
neurotoxicity in the presence of antioxidants For example, Li [98] reported that antioxidant 
vitamins (vitamin A, E and C) have protective effects on the early neurodevelopment of children 
against mercury toxicity. Shichiri [99] also reported that fat-soluble antioxidant tocopherols and 
tocotrienols ameliorate MeHg-induced neurotoxicity using cultured cerebellar granule cells 
(CGCs). Zhang [100] further reported that pyrroloquinoline quinone (PQQ), a novel redox 
cofactor, exhibits the neuroprotective effects on cultured PC12 cells.  
 
MeHg Toxicity in Glia 
After MeHg exposure, approximately 10% mercury is retained in the brain. However, Hg is not 
universally distributed and is preferably deposited in certain CNS cell types. Charleston [101] 
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reported that tissue staining following six months of exposure to MeHg reveals the largest Hg 
deposits in glia including astrocytes and microglia. The total mercury accumulation in neurons is 
significantly lower than those present in the glial cells and increase with the length of exposure; 
virtually all neurons are labeled following 18 months of exposure. In contrast, endothelial cells 
and pericytes do not contain notable mercury deposits, and deposits in oligodendrocytes are 
rarely observed. These data are consistent with the hypothesis that the neurotoxicity of MeHg is 
mediated, at least in part, by glial cells and that glia-neuron interactions play important roles in 
the process. Notably, staining of mercury deposits in inorganic Hg-exposed animals is lower 
compared to MeHg-exposed animals, supporting the observation that it is the organic form of 
mercury that more readily crosses the blood-brain barrier (BBB) [102].  
 
I. MeHg Toxicity in Astrocytes  
Astrocytes are the major glial cell type, which  provide support and nutrition [1], maintain CNS 
homeostasis [103], form myelin [103], participate in signal transmission [104, 105], secret 
growth factors, release of cytokines and modulate synaptic transmission by removal of 
neurotransmitters such as glutamate from the synaptic cleft [104, 105].  
 
MeHg inhibits the astrocytic uptake of cystiene, a crucial precursor for glutathione (GSH) 
synthesis, leading to decreased GSH levels [106]. GSH has been shown to be the key molecule to 
reduce reactive oxygen species. Therefore, intracellular ROS increases after MeHg exposure 
[107]. MeHg also leads to oxidative stress by directly disrupt mitochondrial functions as 
demonstrated by decreased mitochondrial TMRE fluorescence [107]. Astrocytes dysfunction 
also affect nearby neurons. Because astrocytes provide GSH precursors to neurons, MeHg-
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induced decrease in cystiene uptake in astrocytes contributes to neuronal oxidative damage 
[108]. Furthermore, MeHg also inhibits astrocytic glutamate uptake, while stimulating glutamate 
efflux [90, 107], which results in excessive glutamate concentrations in the synapse and, 
consequently, neuronal excitotoxicity. Moreover, a number of previous studies have shown that 
MeHg exposure led to astrocytic dysfunction associated with increased Na+ [109] and aspartate 
uptake [110, 111] and excessive production of excitatory neurotransmitter, affecting the glia-
neuron interaction [112].   
 
II. MeHg Toxicity in Microglia 
Microglia,  derived from myeloid lineage [113], are the second largest glial cell type (typically 8-
12 um in diameter).  The major functions of microglia include phagocytosis and surveillance of 
parenchyma. Microglia also function as antigen presenting cells (APC) by expressing low level 
of Major Histocompatibility Complex (MHC-II) [113]. Physiologically, microglia are not 
isolated from other cell types in the brain; instead, they participate in the formation of cell-
network by close contacting with astrocytes, which mediates and synergizes responses. Notably, 
microglia are the first cell type to become activated in the presence of inflammation, infection, 
and brain trauma [113]. Microglia also play important role in the numerous neurodegenerative 
diseases, such as Alzheimer’s disease [114], Parkinson’s disease [115] and HIV dementia [116]. 
Once activated, microglia produce soluble proinflammatory cytokines, prostaglandins and 
interleukins, such as tumor necrosis factor-α (TNF-α), PGE2, interleukin-1 (IL-1) and 
interleukin-6 (IL-6), which not only contribute to the neighboring neuronal damage, but also 
recruit immune cells into the CNS. Previous literature showed that microglia are more sensitive 
than other CNS cell types to adverse stimuli. For example, Monnet showed that microglial cells 
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respond to adverse stimuli at lower concentrations [117, 118] and such reactions occur prior to 
astrocytic dysfunction and neuronal death [119, 120]. After MeHg exposure, microglia 
accumulate the largest concentration of mercury in non-human primates, which limits the 
amount of free Hg in the CNS [102]. However, the majority of previous studies are focused on 
the MeHg toxicity on neurons and astrocytes [107, 121, 122], but little on microglia. Therefore, 
my thesis project is carried out to answer this question.   
 
Protective Effects of NF-E2-related factor 2 (Nrf2) and its Downstream Genes 
Nrf2 is the primary transcription factor that controls the antioxidant response essential for 
maintaining cellular redox homeostasis in numerous cells, including vascular smooth muscle 
cells [123], mononuclear cells [124] and liver cells [125] etc. Nrf2 also maintains redox balance 
in glia after exposure to the murine leukemia virus [126] and a variety of environmental 
toxicants, such as lipopolysaccharides (LPS) [127] and kainic acid [128]. Under physiological 
conditions, inactive Nrf2 is bound to the Kelch-like ECH-associating protein 1 (Keap1) in the 
cytoplasm [129]. Keap1 functions both as an Nrf2 cytosolic repressor [130] and as an adaptor for 
cullin 3-based E3 ubiquitin ligase, leading to rapid proteasomal degradation of Nrf2 [131, 132]. 
Upon oxidative stress, the interaction between Nrf2 and Keap1 is disrupted, which decreases the 
rate of proteasomal degradation of Nrf2. This causes de novo Nrf2 to build up within the cells, 
leading to increased translocation of Nrf2 into nuclei [133]. In the nucleus, Nrf2 forms 
heterodimers with small Maf proteins, such as FosB, C- Jun, JunD, ATF2 and ATF4 [132, 134, 
135]. These heterodimers interact with the antioxidant response element (ARE) to initiate the 
transcription of target genes including the light chain of the cysteine/glutamate transporter (xCT), 
γ-glutamyl cysteine synthase, hemeoxygenase-1 (Ho-1) and NADPH:quinone oxidoreductase-1 
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(Nqo1), in order to detoxify xenobiotics and endogenous reactive electrophiles [136-138]. 
Furthermore, Nrf2 knockout mice show increased sensitivity to a variety of pharmacological and 
environmental toxicants, such as carcinogens and oxidative stressors such as acetaminophen 
[139, 140]. For example, Das [141] reported that acetaminophen induces cellular injury mainly 
through reducing glutathione level, increasing lipid peroxidation and causing hepatic DNA 
fragmentation which ultimately leads to cellular necrosis. Chan [142] clearly demonstrated the 
importance of Nrf2 in the detoxification of acetaminophen in their recent paper entitled ‘An 
important function of Nrf2 in combating oxidative stress: detoxification of 
acetaminophen’.1 They showed that the toxicity of acetaminophen is markedly augmented in 
Nrf2 knock out mice. The most striking data are that the Nrf2 knock out mice died rapidly 
between 6 and 12 h after injection, whereas the wild-type mice died over a more extended 
period, with the last deaths occurring between 36 and 48 h post injection. The LD50 was 235 and 
320 mg kg−1 for male and female Nrf2 knock out mice, respectively, and 400 and 540 mg 
kg−1 for the male and female wild-type mice, respectively.  
 
As stated above, MeHg causes oxidative stress in glia, therefore, it is reasonable to hypothesize 
that Nrf2-mediated antioxidant machinery is likely to be used in both astrocytes and microglia to 
detoxify the free radicals post MeHg exposure.  
  
 
Hypotheses and Specific Aims  
Given the fact that in the past several decades, the majority of studies on MeHg-induced CNS 
damage have been focused on its effects on neurons and astrocytes [107, 121, 122] and little 
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work has been done on microglial cells, my thesis project was carried out in order to better 
understand mechanisms of MeHg toxicity in glial cells and cellular response after acute MeHg 
exposure. Although previous studies have assessed the effects of high concentrations of MeHg 
after long term of exposure on immortalized microglial cell lines [143, 144], these results may 
not represent the acute response of primary microglial cells to lower concentrations of MeHg as 
detected in the early stage of Minamata disease patients. More importantly, the immortalized 
microglia cell lines derived from cancers may not represent the natural response of primary 
microglia. Given these limitations, it is necessary to characterize primary microglial response to 
MeHg and to test the role of microglial cells in exhibiting an acute response to low 
concentrations of MeHg after short term of exposure.  We hypothesized that 1) the cellular 
responses to MeHg are cell-type specific; 2) there are differences in the uptake of MeHg between 
astrocytes and microglia, leading to differential temporal cellular responses associated with 
oxidative stress. 
 
The aims of my thesis project are 1) assess the acute responses of primary microglia after short 
period of MeHg exposure; 2) investigate and compare the kinetics of microglial activation with 
that of astrocytes; 3) study the function of Nrf2 and its downstream genes including Ho-1, xCT 
and Nqo1 after MeHg exposure in astrocytes and microglia, respectively; 4) determine the 
differences in the kinetics of Nrf2 activation in glial cell subtypes in order to better understand 
their respective roles in mediating adaptive responses to MeHg treatment.  
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CHAPTER II 
 
ACUTE RESPONSE OF RAT PRIMARY MICROGLIAL CELLS TO 
METHYLMERCURY (MeHg) EXPOSURE 
 
This chapter has been published as an article under the title as  
“Methylmercury Induces Acute Oxidative Stress, Altering Nrf2 Protein Level in Primary 
Microglial Cells” 
In Toxicol Sci. 2010 Aug; 116(2):590-603. 
 
Summary 
The neurotoxicity of methylmercury (MeHg) is well documented in both humans and animals. 
MeHg causes acute and chronic damage to multiple organs, most profoundly the central nervous 
system (CNS). Microglial cells are derived from macrophage cell linage, making up ~12% of 
cells in the CNS, yet their role in MeHg-induced neurotoxicity is not well defined. The purpose 
of present study was to characterize microglial vulnerability to MeHg and their potential 
adaptive response to acute MeHg exposure. We examined the effects of MeHg on microglial 
viability, reactive oxygen species (ROS) generation, glutathione (GSH) level, redox homeostasis 
and Nrf2 protein expression. Our data showed that MeHg (1-5 M) treatment caused a rapid 
(within 1 min) concentration- and time-dependent increase in ROS generation, accompanied by a 
statistically significant decrease in the ratio of GSH and its’ oxidized form glutathione disulfide 
(GSSG) (GSH/GSSG ratio). MeHg increased the cytosolic Nrf2 protein level within 1 min of 
exposure, followed by its nuclear translocation after 10 min of treatment. Consistent with the 
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nuclear translocation of Nrf2, quantitative real-time PCR revealed a concentration-dependent 
increase in the mRNA level of Ho-1, Nqo1 and xCT 30 min post MeHg exposure, while Nrf2 
knockdown greatly reduced the upregulation of these genes. Furthermore, we observed increased 
microglial death upon Nrf2 knockdown by the shRNA approach. Taken together, our study has 
demonstrated that microglial cells are exquisitely sensitive to MeHg and respond rapidly to 
MeHg by upregulating the Nrf2-mediated antioxidant response.  
 
Introduction 
Except neurons, the majority non-electrically excitable cells in the CNS are glial cells, including 
astrocytes, microglial cells and small amount of oligodendrocytes. Glial cells have diverse 
functions, such as providing support and nutrition [1], maintaining CNS homeostasis [103], 
forming myelin [103] and participating in signal transmission [104, 105], just to name a few. The 
majority of glial cells are astrocytes, which are intimately involved in maintaining the 
extracellular milieu. Some selected functions of astrocytes include secretion of growth factors, 
release of cytokines and modulation of synaptic transmission by removal of neurotransmitters 
such as glutamate from the synaptic cleft. Oligodendrocytes are the myelin-forming cells in the 
CNS and are analogues to Schwann cells of the peripheral nervous system.  
 
Microglial cells comprise approximately 12% of total cell population in the brain and are the 
second largest glial cell type. Microglia are derived from myeloid lineage [113]. In postnatal 
rodents, immunocytochemical studies using antibodies to F4/80 (ERM1), CR3 and FcγRII/III 
establish that the microglia enter the brain from the circulation and are derived from circulating 
monocytes [113]. In the brain, they possess phagocytic activity and survey the parenchyma. 
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Microglia express low level of Major Histocompatibility Complex (MHC-II) and function as 
antigen presenting cells (APC) of the CNS [113]. They are in close contact with other cells in the 
brain, mainly astrocytes, thus establishing cross-talk that mediates and synergizes responses both 
in physiological and pathological conditions. Under optimal conditions microglial surface 
receptors, such as TREM2 and Siglecs, maintain the microglia in an inactivated state [113]. In 
the presence of inflammation, infection, trauma and degenerative diseases, microglial cells are 
the first cell type to become activated. Their activation is inherent to Alzheimer’s disease [114], 
Parkinson’s disease [115], HIV dementia [116] as well as numerous other pathological 
conditions. Once activated, microglia produce soluble proinflammatory cytokines, 
prostaglandins and interleukins, such as tumor necrosis factor-α (TNF-α), PGE2, interleukin-1 
(IL-1) and interleukin-6 (IL-6), which not only contribute to the neighboring neuronal damage, 
but also recruit immune cells into the CNS.   
  
MeHg affects neurons and glial cells in the CNS both acutely and chronically. In the past several 
decades, the majority of studies on MeHg-induced CNS damage have focused on its effects on 
neurons and astrocytes [107, 121, 122]. It has been reported that MeHg disrupts cellular redox 
homeostasis through excessive ROS generation. The interaction of MeHg with the mitochondrial 
electron transport chain (ETC) represents a major mechanism of MeHg-induced ROS generation 
[91]. It causes a concentration-dependent reduction of the inner mitochondrial membrane 
potential [107] by altering Ca2+ homeostasis [145]. MeHg also decreases ATP synthesis in 
neurons by inhibiting both glycolysis and the Krebs cycle [146], thereby contributing to neuronal 
dysfunction and death. Furthermore, MeHg inhibits astrocytic glutamate uptake, while 
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stimulating glutamate efflux [90], consequently resulting in an excessive concentration of 
synaptic glutamate, which ultimately leads to neuronal excitotoxicity and cell death [147].  
 
Until recently, the toxicity of MeHg on primary microglial cells has not been fully investigated. 
More and more evidences suggesting the import role of microglial cells in mediating MeHg 
induced brain toxicity. For example, comparative studies carried out in animals treated with 
neurotoxins have shown that microglial cells react at lower concentrations [117, 118] and that 
such reactions occur prior to astrocytic dysfunction and neuronal death [119, 120]. Monnet 
reported that the earliest sign of MeHg-induced neurotoxicity was inherent to microglial cells by 
using three-dimensional brain cell cultures [148]. Consistently, Charleston et al. reported that 
microglial cells accumulated the largest concentration of mercury following MeHg exposure in 
non-human primates [102]. Although some studies have assessed the effects of high 
concentrations of MeHg after long times of exposure on immortalized microglial cell lines [143, 
144], these results may not represent the acute response of primary microglial cells to lower 
concentrations of MeHg as detected in the early stage of Minamata disease patients. Given 
existing limitations, it is necessary to characterize microglial vulnerability to MeHg and to test 
the role of microglial cells in exhibiting an acute response to low concentrations of MeHg after 
short times of exposure.  
 
Here, for the first time, we assessed microglial functional changes after short-term exposure to 
MeHg concentrations, which failed to elicit detrimental effects in other cell types. For example, 
MeHg treatment at concentrations lower than 5 µM did not cause decrease in formazan 
production (MTT assay) or oxidative stress in rat striatal synaptosomes [149]. Similar results 
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were also observed in primary rat astrocytes where MeHg at concentrations lower than 5 µM 
failed to elicit ROS production [150]. 
 
Analogous to other cell types, the generation of ROS in microglial cells by MeHg plays a critical 
role in its toxicity [144]. The Nrf2-mediated antioxidant machinery is likely used in microglial 
cells to detoxify free radicals. Nrf2 maintains redox balance in microglial cells after exposure to 
the murine leukemia virus [126] and a variety of environmental toxicants, such as 
lipopolysaccharides (LPS) [127] and kainic acid [128]. Under physiological conditions, inactive 
Nrf2 is bound to the Kelch-like ECH-associating protein 1 (Keap1) in the cytoplasm [129]. 
Keap1 functions both as an Nrf2 cytosolic repressor [130] and as an adaptor for cullin 3-based 
E3 ubiquitin ligase, leading to rapid proteasomal degradation of Nrf2 [131, 132]. Upon oxidative 
stress, the interaction between Nrf2 and Keap1 is disrupted, decreasing the rate of proteasomal 
degradation of Nrf2. This causes de novo Nrf2 to build-up within the cells, leading to increased 
translocation of Nrf2 into the nuclei [133]. In the nucleus, Nrf2 forms heterodimers with small 
Maf proteins, such as FosB, C- Jun, JunD, ATF2 and ATF4 [132, 134, 135]. These heterodimers 
interact with the antioxidant response element (ARE) to initiate the transcription of target genes 
including the light chain of the cysteine/glutamate transporter (xCT), γ-glutamyl cysteine 
synthase, hemeoxygenase-1 (Ho-1) and NADPH:quinone oxidoreductase-1 (Nqo1), in order to 
detoxify xenobiotics and endogenous reactive electrophiles [136-138]. Furthermore, Nrf2 
knockout mice show increased sensitivity to a variety of pharmacological and environmental 
toxicants, such as carcinogens and acetaminophen [139, 140]. Therefore, it is important to 
explore the role of Nrf2 in MeHg toxicity in microglial cells.   
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The present study was carried out to test the hypothesis that microglial cells are exquisitely 
sensitive to MeHg and that they undergo rapid activation upon being treated with low 
concentrations of MeHg (0.1~ 5M), representative of common environmental exposure levels 
[151]. We found that acute MeHg treatment immediately resulted in ROS generation, GSH 
depletion and, consequently, the upregulation of both Nrf2 protein and the expression of Ho-1, 
Nqo1 and xCT in primary microglial cells. Nrf2 knockdown attenuated the upregulation of such 
genes, resulting in increased microglial death upon MeHg exposure. 
 
Experimental Procedures 
Primary Microglial Culture 
Primary microglial cells were isolated and cultured according to a published protocol [152]. 
Briefly, the cerebral hemispheres of postnatal day-1 neonatal Sprague-Dawley rats were removed 
and the meninges were dissected off. The cortical tissue was digested with dispase (BD 
Biosciences, Two Oak Park Dr. Bedford, MA, USA). The mixed glial cell culture was 
maintained in minimum essential medium (MEM) (Invitrogen, Carlsbad, CA, USA), 
supplemented with 5% heat-inactivated fetal bovine serum (Hyclone, South Logan, Utah, USA) 
and 5% horse serum (Invitrogen, Carlsbad, CA, USA). The media were changed once a week. 
After two weeks in culture, microglial cells were separated by gentle shaking for 20 min at room 
temperature and then plated in 6-well plates and cultured at 37°C in a 95% air/5% CO2 incubator 
for additional 48 hours in MEM containing 10% fetal bovine serum (Hyclone, South Logan, 
Utah, USA) and 1% penicillin and streptomycin (Invitrogen, Carlsbad, CA, USA). The purity of 
the cells was determined by immunostaining for the microglia specific marker, OX42 (sc-53086, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA); cell nuclei were counter-stained with 4',6-
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diamidino-2-phenylindole  (DAPI) (VECTASHIELD Mounting Medium with DAPI, H-1200, 
Burlingame, CA, USA).  
MTT Assay and LDH Assay 
The cytotoxic effect of MeHg in microglial cells was evaluated by 3-[4,5- dimethylthiazol-2-yl]-
2,5 diphenyltetrazolium bromide (MTT) assay (Sigma in vitro Toxicology Assay Kit, MTT 
based, M-5655, St. Louis, MO, USA). 10X MTT stocking solution was prepared by 
reconstituting 15mg stock MTT reagent in 3ml of OPTI- MEM culture media (Invitrogen, 
Carlsbad, CA, USA) in the absence of phenol red immediately before the experiment. Primary 
cultured microglial cells were maintained in 96-well plates at a density of 20,000 cell/well for 2 
days prior to experiment. Cells were treated for 6 hours. Treatment with 100 M H2O2 was used 
as a positive control of cell death.  After treatment, 10X MTT stocking solution was directly 
added to each well at a final concentration of 0.5 mg/ml. The formazan crystal precipitates were 
dissolved by adding an equal volume of MTT solubilization solution (Sigma, M-8910, St. Louis, 
MO, USA) and gently shaking for 20 min. The absorbance was measured by spectrophotometer 
(Molecular Device, VMax® Kinetic Microplate Reader, Sunnyvale, CA, USA) at a wavelength 
of 570 nm. The background absorbance was measured at 690 nm and subtracted from the 570 
nm measurement. 
 
Cellular membrane integrity was measured by the lactate dehydrogenase (LDH) assay. After 
treatment, the culture media were collected for LDH analysis. The LDH assay substrate (L 2402, 
Sigma, St. Louis, MO, USA) was always freshly prepared. The assay mixture was added in an 
amount equal to twice of the volume of the culture medium and incubated at room temperature 
for 30 min in the dark. The reaction was terminated by adding 1/10 volume of 1N HCL. The 
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absorbance was measured by a spectrophotometer (Molecular Device, VMax® Kinetic 
Microplate Reader, Sunnyvale, CA, USA) at a wavelength of 490 nm, and the background 
absorbance was measured at 690nm.  
 
Detection of intracellular ROS formation  
Microglial cells were pre-incubated with H2DCF-DA (C6827, Invitrogen, Carlsbad, CA, USA) at 
a final concentration of 25 M for 30 min at 37C. The MeHg solution was directly added in the 
MEM culture media containing H2DCF-DA. After treatment, the microglial cells were washed 
with 4°C PBS twice and precipitated by centrifugation at 400x g. The cell pellets were then 
dissolved in 1% Triton X- 100 (Promega, Madison, Wisconsin, USA). Fluorescence was 
measured at a wavelength of 480/530nm (excitation/emission) by SpectraMax M5 (Molecular 
Devices, Sunnyvale, CA, USA). The DCF fluorescent signal in microglial cells was obtained 
with a Nikon microscope (Nikon Eclipse 80i, Shinagawa-ku, Tokyo, Japan) at 480/530nm.  
 
Measurement of GSH 
The intracellular GSH concentration was measured by high-performance liquid chromatography 
(HPLC) as previously described [153]. After MeHg treatment, microglial cells were derivatized 
with iodoacetic acid and dansyl chloride. HPLC analysis was carried out with a propylamine 
column (YMC Pack, NH2, Waters, Milford, MA, USA) and an automated HPLC system 
(Alliance 2695, Waters Corporation, Milford, MA, USA). The GSH and GSSG concentrations 
were normalized to the protein concentration of the samples as measured by colorimetric 
detection and quantitation using BCA Protein Assay Reagent (23225, Rockford, IL, USA).    
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Immunohistochemistry 
Microglial cells were cultured on coverslips coated with poly-L-lysine. After MeHg treatment, 
cells were fixed with ice-cold 4% paraformaldehyde (PFA) for 15 min, followed by two washes 
with 30 mM glycine to quench the PFA. Cells were permeated for 3 min by 0.25% Triton X- 100 
in PBS and blocked in 5% BSA/PBS for 45 min. The samples were incubated for 1h with 1:200 
rabbit anti- Nrf2 (Abcam 31136, Cambridge, MA, USA) and washed in PBS three times before 
incubation with 1:400 secondary antibody, donkey anti-rabbit IgG conjugated with FITC 
(Millipore, AP182F, Billerica, MA). Coverslips were mounted with Vectashield Mounting 
Medium with Propidium Iodide (PI) (VECTOR, H-1300, Burlingame, CA, USA). The 
fluorescence signal was detected using a Zeiss confocal microscope (LSM 510, Zeiss, Dublin, 
CA, USA) at the following settings: detector gain 900, amplifier offset -0.085 and pinhole 98. 
The propidium iodide (PI) signal was detected with the following settings: detector gain 844, 
amplifier offset -0.068 and pinhole 110.  
 
Measurement of Nrf2 by Western Blot Analysis 
Western blot analysis was conducted with the primary antibodies, rabbit-anti Nrf2 (1:400) (sc- 
722, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse anti β-Actin (1:2,000) 
(A1978, Sigma, St. Louis, MO, USA). Secondary antibodies were donkey anti-rabbit IgG 
conjugated with horseradish peroxidase (HPR) (1:1000) (W4011, Promega, Madison, Wisconsin, 
USA ) and donkey anti-mouse IgG conjugated with horseradish peroxidase (HPR) (1:4,000) 
(W4021, Promega, Madison, Wisconsin, USA). The cytosolic and nuclear fractions were 
prepared with NE-PER Nuclear and Cytosolic Extraction Reagents (78833, Thermo Scientific, 
Rockford, IL, USA). Briefly, after treatment, microglial cells were lysed in ice-cold hypotonic 
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buffer containing 10mM HEPES, 1.5mM MgCl2, 10mM KCl and 1mM dithiothreitol (DTT) and 
cocktail of protease inhibitors (Thermo Scientific, Rockford, IL, USA). After 30 min incubation 
on ice, the samples were centrifuged at 4°C at 12,000g and the supernatant was collected as the 
cytosolic fraction. The pellet was further extracted for 30 min in a high salt lysis buffer 
containing 50mM HEPES, 500 mM NaCl, 1 mM dithiothreitol (DTT) and protease inhibitors 
(Thermo Scientific, Rockford, IL, USA). After 10 min centrifugation at 4°C at 12,000g, the 
supernatant was collected as the nuclear fraction. The density of the Nrf2- specific bands was 
normalized to β-Actin.  
 
Measurement of Ho-1, Nqo1 and xCT Genes Expression by Quantitative Real-Time PCR 
mRNA of Ho-1, Nqo1 and xCT were measured by real-time PCR using the Universal Probe 
Library (Roche, Indianapolis, IN, USA). Table 1 lists the primer sequences and UPL probes. 
Average threshold cycle (ΔCt) values were used to determine the relative difference between 
control and treated samples. All data were normalized to -Actin levels.  
 
Table 1 
 
 
Table 1: Primer sequences and UPL probe numbers used to measure expression levels of Ho-1, 
Nqo1 and xCT  in real-time PCR.  
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Nrf2 Knockdown by Small Hairpin RNA (shRNA)  
Primary microglial cells at ~50-60% confluence were infected with 15µl lentiviral particles with 
1X106 infectious units of virus (IFU) for 24 hours. The lentiviral particles contained an 
expression construct encoding specific shRNA against Nrf2 (sc-37049-V, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). The infection rate was tested by copGFP Control 
Lentiviral particles (sc-108084, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Primary 
microglial cells were also infected with control lentiviral particles containing scrambled shRNA 
sequence (sc-108080, Santa Cruz Biotechnology, Santa Cruz, CA, USA) as a negative control.  
 
Statistical analysis 
All results were expressed as means ± standard errors. Unless otherwise specified, differences 
among treatment groups were analyzed by one-way analysis of variance (ANOVA), followed by 
Bonferroni’s post hoc test. Statistical significance was set at p<0.05. All experiments were 
repeated with at least three independently isolated microglial cultures, and data analysis was 
carried out with GraphPad Prism (GraphPad Software, San Diego, CA, USA).  
 
Results 
Overall Cytotoxic Effects of MeHg on Microglia 
As the first step, the purity of primary microglial cultures was assessed by immunostaining with 
the microglial specific marker, OX42 [154] (Fig 2A). As shown in the merged image (Fig 2C), 
when co-stained with DAPI (Fig 2B), a nuclear dye, nearly all cells appeared to be of the 
microglial cells lineage. In addition, cells exhibited characteristic microglial morphology in the 
differential interference contrast (DIC) image (Fig 2D).  
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Fig 2 
 
 
 
 
 
Fig 2. The purity of primary microglial culture was tested on day 3 after separation from mixed 
glial culture by immunostaining for OX42. [A]: Microglial cells were fixed and immunostained 
for OX42. [B]: Microglial nuclei were counter-stained with DAPI. [C]: Merged image of OX-42 
and DAPI demonstrated the purity of microglial culture close to 100%. [D]. DIC image of 
microglial cells. Photographs show representative fields observed in twelve coverslips from three 
independent experiments.  
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Next, we tested the overall cytotoxic effects of MeHg on microglial cells with the MTT assay. 
The absorbance of MTT (wavelength of 570nm) is positively correlated with cell viability. As 
shown in Fig 3A, after MeHg treatment for 6 hours, the absorbance was indistinguishable 
between control and 0.1M MeHg-treated cells. However, higher concentrations of MeHg (1 and 
5 M) reduced the absorbance to 0.86± 0.09 (p<0.05) and 0.59± 0.08 (p<0.001), respectively, 
reflecting reduced cell viability. As the positive control, H2O2 at 100 M reduced MTT 
absorbance to 0.27± 0.07 (p<0.001). Cell viability was also measured by the LDH assay. The 
absorbance of LDH (wavelength of 490nm) is reversely correlated with cell viability. As shown 
in Fig 3B, the absorbance of LDH increased after 6-hour treatment with 1 (p<0.01) and 5 M 
MeHg (p<0.001), respectively, reflecting decreased cell viability.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
 
Fig 3A 
 
Fig 3B  
 
Fig 3. Effect of MeHg cytotoxicity on microglial cells was measured by MTT assay [A] and 
LDH assay [B]. [A]: Result of MTT assay of microglial cells after MeHg treatment for 6h 
showed the concentration-dependent decrease in absorbance. Microglial cells were treated with 
MeHg with the concentrations indicated in the graph. 100µM H2O2 was used as a positive 
control. [B]: Result of LDH assay using microglial culture media after the same treatment 
demonstrated a concentration-dependent increase in absorbance. Values are expressed as the 
mean ± SEM derived from five independent experiments. 
P<0.05, P<0.01, P<0.001  
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MeHg Caused Acute Oxidative Stress in Microglia  
Next, we tested whether MeHg induces ROS generation in microglial cells with the H2DCF-DA 
assay. The lipophilic H2DCF-DA diffuses freely through the cell membrane and it is 
intracellularily converted to hydrophilic DCF. Once in the cells, DCF reacts with ROS and 
fluoresces, providing a tool for intracellular ROS level analyses. As shown in Figure 4, a 
significant increase in fluorescence intensity was readily detectable after 1min treatment with 5 
M MeHg (222.6±39.01, p<0.01) and 100 M H2O2 (229.03±40.08, p<0.001).  Treatments with 
1M and 5 M MeHg for 10 min further increased DCF fluorescence in a concentration-
dependent manner (Fig 4). Furthermore, increased DCF fluorescence in living microglial cells 
was also visualized under a Nikon microscope at 480/530nm corroborating the findings in Fig 4 
(see Fig 5).  
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Fig 4 
 
 
 
 
Fig 4. ROS production was measured by DCF fluorescence in microglial cells. Microglial cells 
were treated with MeHg at the concentrations indicated in the graph. 100µM H2O2 was used as a 
positive control. DCF fluorescence levels were measured after 1 min and 10 min treatment, 
respectively. The results demonstrated that higher MeHg concentration and longer exposure time 
led to higher ROS level. Values are expressed as the mean ± SEM derived from six independent 
experiments. P<0.05, P<0.01, P<0.001  
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Fig 5A 
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Fig 5B  
 
 
 
Fig 5. DCF fluorescence levels in living microglial cells were visualized by microscopy.  [5A]: 
Microglial cells were treated with MeHg at the concentrations indicated in the figures. 100µM 
H2O2 was used as a positive control for 1 min. [5B]: Microglial cells were treated under the same 
concentrations for 10 min. The intensity of the fluorescence signal was indicative of the 
intracellular ROS production. Photographs show representative fields observed from three 
independent experiments.  
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MeHg Caused Microglial GSH Reduction  
GSH can detoxify ROS, resulting in the formation of GSSG, the oxidized form of GSH. 
Therefore, we sought to determine if microglial ROS generation could cause a decline in the 
GSH level. As shown in Fig 6, after 0.1 M MeHg treatment for 1 min, the GSH/GSSG ratio 
remained statistically unchanged as compared to the control. However, higher concentrations of 
MeHg (1 and 5 M) produced a concentration-dependent reduction in the GSH/GSSG ratio 
(69.01±16.9% and 51.32±20.9% of the control level, respectively). Further reduction in the 
GSH/GSSG ratio was observed after prolonged MeHg treatment for 10min and 1h in a 
concentration- and time-dependent manner. 
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Fig 6 
 
 
 
 
 
Fig 6. GSH and GSSG levels were measured by HPLC after MeHg treatment. Microglial cells 
were treated with MeHg at the concentrations indicated in the graph for 1min, 10min and 1h. 
100µM H2O2 was used as a positive control. The ratios of GSH/GSSG were calculated and the 
percentages of control were used to plot the graph. Each treatment group was compared to its 
corresponding control level. The results demonstrated that MeHg caused acute and robust 
reduction in microglial GSH level in a concentration- and time-dependent manner. Values are 
expressed as the mean ± SEM derived from three independent experiments. 
P<0.05, P<0.01, P<0.001  
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MeHg–induced Oxidative Stress Upregulated Nrf2 and Promoted its Nuclear 
Translocation  
As mentioned before, Nrf2 plays a pivotal role in maintaining redox balance. Therefore, we 
sought to determine if Nrf2 was altered in microglial cells post MeHg exposure in order to 
counteract ROS generation. Indeed, the upregulation of the Nrf2 protein level and its nuclear 
translocation were detected in microglial cells by confocal microscopy after MeHg exposure. As 
shown in Fig 7, the basal level of Nrf2 (green fluorescence) was low. After 10 min treatment 
with 0.1 M MeHg, Nrf2 staining was sparsely detected in the cytosol. In contrast, treatment 
with 1 or 5 M MeHg increased Nrf2 staining in both the cytosol and nuclei. Compared to 1 M 
MeHg treatment, the staining intensity was greater in 5M MeHg-treated cells. The co-
localization of Nrf2 and propidium iodide (PI) staining in the nuclei indicated the nuclear 
translocation of Nrf2.  
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Fig 7 
 
 
 
Fig 7. Nrf2 protein level and intracellular localization were assessed by immunostaining. [A]: 
Control group showed minimal Nrf2 (Green) in the cytosol. Cell nuclei were stained by PI (Red). 
[B]: 0.1M MeHg treatment increased Nrf2 in the cytosol, but not in the nuclei. [C]: 1M MeHg 
treatment for 10 min increased Nrf2 in both the cytosol and the nuclei. [D]: 5M MeHg 
treatment for 10 min resulted in a higher level of Nrf2 in both cytosol and nuclei, as compared to 
1M MeHg-treated cells. The yellow color indicates the colocalization of Nrf2 and DNA in 
microglial nuclei. Photographs show representative fields observed from four independent 
experiments.  
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Next, we delineated the dynamic changes in Nrf2 level in both the cytosol and nuclei. As shown 
in Fig 8, cytosolic Nrf2 protein increased in a concentration-dependent manner after 1 min 
MeHg treatment. However, under the same conditions, the nuclear Nrf2 protein level remained 
unchanged. After 10 min, Nrf2 protein level was increased in both the cytosolic and nuclear 
fractions after 1 and 5 M MeHg treatments as well as 100 M H2O2 treatment. After 1 h of 
MeHg treatment, increased Nrf2 accumulated in the nuclei, but not in the cytosol. The 
quantitative results in Fig 8 show that 1 and 5M MeHg treatment for 1 hour increased nuclear 
Nrf2 by 2.60±0.56- (p<0.05) and 3.99±1.32- (p<0.01) fold over the control value, respectively. 
The representative western blot bands are shown below the quantified data in Fig 8.  
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Fig 8 
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Fig 8. Cytosolic and nuclear fractions of Nrf2 were analyzed by western blot. Microglial cells 
were treated with MeHg at the concentrations indicated in the graph for 1min, 10min and 1h. 
100µM H2O2 was used as a positive control.Nrf2 protein levels in cytosolic and nuclear fractions 
were measured by western. Density of each band was measured by Image J, and the values were 
normalized with β-Actin. After 1 min MeHg treatment, Nrf2 increased in the cytosolic fraction 
but not in the nuclear fraction. After 10 min MeHg treatment, however, Nrf2 increased in both 
subcellular fractions. After 1 h MeHg treatment, Nrf2 remained increased in the nuclear fraction, 
but returned to control level in the cytosol. Values are expressed as the mean ± SEM derived 
from three independent experiments. P<0.05, P<0.01, P<0.001  
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MeHg-induced Nrf2 Nuclear Accumulation Upregulated the Transcription of Ho-1, Nqo1 
and xCT Genes  
After treatment with MeHg for 30 min, the mRNA levels of Ho-1, Nqo1 and xCT were 
quantified by real-time PCR. The treatment time was based on the observation that Nrf2 was 
translocated to the nuclei commencing at 10 min post MeHg treatment and remained detectable 
at 1 hour post treatment. The transcription level of Ho-1 (Fig 9A) and Nqo1 (Fig 9B) was 
upregulated in response to MeHg treatment with 1 and 5 μM. However, xCT gene expression 
was increased by 2.3±1.46-fold over the control value (p<0.01) after treatment with the highest 
concentration of MeHg (5 M), as shown in Fig 9C.  
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Fig 9A 
 
Fig 9B 
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Fig 9C 
 
 
 
Fig 9. The expression of Ho-1, Nqo1 and xCT were measured by real-time PCR after MeHg 
treatment. Microglial cells were treated with MeHg at the concentrations indicated in the graph 
for 30min. 100µM H2O2 was used as a positive control. The mRNA levels of Ho-1 [8A], Nqo1 
[8B] and xCT [8C] were measured by real-time PCR. The differences in the average threshold 
cycle (ΔCt) values were determined and normalized to the expression of β-actin. Values are 
expressed as the mean ± SEM derived from five independent experiments. 
P<0.05, P<0.01, P<0.001  
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Next, we carried out an Nrf2 knockdown experiment to confirm that the transcriptional 
upregulation of these tested genes is dependent on Nrf2 activity. Compared to the control group, 
5 M MeHg treatment caused a significant increase in the Ho-1 mRNA levels in both uninfected 
and scramble shRNA-infected microglial cells (p<0.05). In contrast, the Nrf2 knockdown group 
did not demonstrate an increased Ho-1 mRNA level after the same treatment as compared to the 
control level (p>0.05) (Fig 10A). Fig 10B shows that no significant increase in Nqo1 mRNA 
level was present in the Nrf2 knockdown group after 5µM MeHg, in contrast to uninfected or 
scramble shRNA-treated groups. Similar changes in xCT mRNA level were also observed after 
Nrf2 knockdown (Fig 10C). Therefore, the upregulation of Ho-1, Nqo1 and xCT transcription 
upon MeHg treatment is dependent upon nuclear Nrf2 activity. 
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Fig 10A 
 
Fig 10B 
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Fig 10C 
  
 
F 
 
Fig 10. The effects of Nrf2 knockdown on MeHg-induced Ho-1, Nqo1 and xCT expression were 
analyzed by real-time PCR. Primary microglial cells were first infected with lentivirus as 
indicated for 24 hours and then treated with 5M MeHg for 30 min. Then, the mRNA levels of 
Ho-1 [9A], Nqo1 [9B] and xCT [9C] were measured by real-time PCR. The difference in the 
average threshold cycle (ΔCt) values was determined and normalized to the expression of β-
actin. The uninfected and untreated microglial cells were used to determine the basal gene 
expression levels. The uninfected cells treated with 5M MeHg for 30min served as a positive 
control. The random virus with no known gene target was also used to infect microglial cells in 
order to reveal any possible effects of lentiviral backbone on gene expression. Microglial cells 
treated Nrf2 specific shRNA showed no significant increase in downstream gene expression 
compared to basal levels after 5uM MeHg treatment for 30min. Values are expressed as the 
mean ± SEM derived from three independent experiments. 
P<0.05, P<0.01, P<0.001  
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Nrf2 Protected Microglial Cells against MeHg Toxicity 
To further evaluate the cytoprotective function of Nrf2 against MeHg-induced cell death, we 
assessed cell viability upon MeHg treatment under Nrf2 knockdown condition. As shown in Fig 
11A, compared to uninfected microglial cells in the absence of MeHg exposure, both uninfected 
cells and random virus infected cells treated with 5M MeHg for 6h demonstrated a significant 
decrease in MTT absorbance; , knockdown of Nrf2 further decreased MTT absorbance after the 
same treatment (p<0.001). Notably, compared to uninfected cells post MeHg treatment, 
knockdown of Nrf2 caused a significant decrease in MTT absorbance (p<0.001, compare 2nd 
column with 4th column in Fig 11A). Consistent with the MTT assay results, the Nrf2 
knockdown group demonstrated the highest absorbance after 5M MeHg treatment for 6h in the 
LDH assay (Fig 11B). Furthermore, compared to uninfected microglial cells treated with MeHg, 
Nrf2 knockdown of microglia displayed increased LDH absorbance, indicating decreased 
viability in Nrf2 deficienct cells (p< 0.001, compare 2nd column with 4th column of Fig 11B).  
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Fig 11 A 
 
Fig 11 B 
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Fig 11. The effects of Nrf2 knockdown on microglial cell viability were assessed by MTT and 
LDH assay. Primary microglial cells were first infected with lentivirus for 24 hours and then 
treated with 5M MeHg for 6h. The uninfected microglial cells without MeHg exposure were 
used to measure the maximal cell viability. The uninfected cells treated with 5M MeHg for 6h 
served as a positive control for cell death. The random virus with no known gene target was also 
used to infect microglial cells in order to reveal any possible cytotoxicity effects of the lentiviral 
backbone [A]: Result of MTT assay showed lowest absorbance in Nrf2 knockdown cells, 
indicative of lowest cell viability [B]: Result of LDH assay using culture media from the same 
treatment groups demonstrated the  highest absorbance in Nrf2 knockdown cells, which indicated 
the highest level of LDH released from damaged microglial cells to culture media. Values are 
expressed as the mean ± SEM derived from four independent 
experiments. P<0.05, P<0.01, P<0.001  
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Discussion 
To our knowledge, this is the first study to investigate the response of primary microglial cells to 
acute MeHg exposure. We have demonstrated that MeHg leads to rapid ROS generation and 
GSH depletion commencing at one minute post MeHg exposure, well before changes in 
astrocytes or neurons are observed (data not shown). In response, microglial Nrf2 is upregulated 
and undergoes nuclear translocation to activate the expression of downstream genes such as Ho-
1, Nqo1 and xCT. Our data suggest that microglial cells are the first line of cellular defense 
against MeHg toxicity in the CNS.  
 
Previous studies have reported an increase in ROS in microglial cells after prolonged MeHg 
treatment at high concentrations [143, 144, 155]. However, these studies do not capture the acute 
microglial response to lower concentrations of MeHg as detected in early stage of Minamata 
disease patients.  Here, we have revealed that 5M MeHg exposures cause a significant increase 
in ROS generation in primary microglial cells commencing at one minute post MeHg exposure 
(Fig 4, 5). Similar acute ROS generation in microglial cells was also observed after TiO2 
exposure [156]. Although increased generation of ROS also occurs in neurons [157, 158] and 
astrocytes [107, 153], it is only detected after much longer exposure to MeHg. 
 
GSH is used to detoxify ROS and itself is converted to the oxidized form, GSSG. In response to 
MeHg, microglial ROS is increased (Fig 4,5) and, correspondingly, the GSH/GSSG ratio is 
decreased (Fig 6). Previous studies have established the cytoprotective effects of GSH in MeHg-
induced toxicity [159, 160]. GSH binds to Hg compounds via its sulfhydryl groups, and the 
conjugated products are actively pumped out of the cells by multidrug resistance proteins 
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(MRPs), leading to the decrease in intracellular Hg and its toxicity [161]. Our data have also 
revealed that a lower intracellular GSH level is correlated with greater microglial death. For 
example, treatment with 5M MeHg causes maximal reduction in GSH levels (Fig 6) as well as 
maximal cell death (Fig 3). In agreement with our observations, Miura and Clarkson reported a 
significant inverse correlation between the GSH level and MeHg toxicity using a MeHg-resistant 
rat pheochromocytoma PC12 cell line. The levels of GSH in these resistant cells were four-fold 
higher than in the nonresistant cells, which led to greater efflux and less intracellular retention of 
MeHg [162, 163]. Furthermore, microglial GSH levels are only 25% of those in astrocytes (data 
not shown), which likely reflects their diminished capability to buffer MeHg-induced ROS 
generation. In addition, lower GSH levels in microglial cells may lead to reduced MeHg efflux 
and increased intracellular Hg levels. This may explain previous findings of the earliest and 
highest accumulation of Hg deposits in microglial cells in the rat brain [164] and non-human 
primates [102].  
 
Intracellular ROS generation is the pivotal event in regulating Nrf2 levels [153]. As the major 
regulator of the antioxidant system in cells, Nrf2 protein levels in microglia increased rapidly 
within 1 min of MeHg treatment (Fig 8). The increase in Nrf2 (Fig 8) protein levels was 
paralleled by the MeHg-induced increase of ROS (Fig 4, 5), as well as the decrease in GSH (Fig 
6). We also observed Nrf2 nuclear translocation commencing at 10 min post MeHg exposure. 
Our data corroborate Li’s model supporting a role for oxidative stress in disrupting the 
interaction between Nrf2 and Keap1, which leads to decreased rate of proteasomal degradation 
of Nrf2 in the cytosolic fraction. This model explains why the increase of cytosolic Nrf2 was 
detected as early as 1 min post MeHg exposure [133]. Based on the fact that Nrf2 activation was 
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not observed in primary astrocytes until 90 min after MeHg treatment at the same concentration 
[153], our results support the notion that microglia are the first glial cell type to respond to MeHg 
[165].  
 
We observed increased microglial death upon Nrf2 knockdown with the shRNA approach       
(Fig 11). Consistent with our result, Toyama et al. reported that primary mouse hepatocytes 
isolated from Nrf2- deficient mice were highly susceptible to MeHg-induced cytotoxicity, and 
Nrf2 overexpression attenuated MeHg-induced cytotoxicity in SH-SY5Y neuroblastoma cells 
[166]. Nuclear translocation of Nrf2 is critical for attenuation of oxidative stress. Once in the 
nuclei, Nrf2 orchestrates the expression of Ho-1, Nqo1 and xCT, all of which detoxify 
xenobiotics and endogenous reactive electrophiles. Previous studies have also confirmed the 
critical function of Nrf2 in regulating the expression of these genes in other cell types. For 
example, in human lumphoma cells, gallium nitrate upregulated the Ho-1 mRNA level as a result 
of Nrf2 activation [153, 167]. Similarly, Nrf2 in renal epithelial cells upregulated the Nqo1 
reporter construct after exposure to hypoxia/reoxygenation [168]. 
 
Upon activation, microglial cells secrete numerous bioactive factors such as interleukins, 
prostaglandin, TNF-α and nitric oxide (NO). The nature of the released factors appears to be 
dependent on the nature of the causative agents. For example, lipopolysaccharides (LPS) and 
trimethyltin (TMT) were reported to increase the microglial release of IL-6, TNF-α and NO 
[143]. In contrast, MeHg leads only to IL-6 release, leaving TNF-α and NO unchanged [155]. As 
the first cell type to respond to MeHg, the microglial response to this metal may influence other 
cell types via the secretion of IL-6. Current literature suggests that IL-6 has differential effects on 
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different cell types. For example, microglial IL-6 induces astrogliosis, associated with MeHg-
induced microglial clusters in 3D brain cell cultures. In contrast, neurons were decreased in the 
vicinity of such clusters [143]. Interestingly, as a proinflammatory factor, IL-6 may have a 
neuroprotective function. IL-6 co-administered with MeHg prevented MeHg-induced 
degeneration of the neuronal cytoskeleton [143]. Similar protective effects of IL-6 against the 
toxic effects of glutamate have also been previously described [169] and MPP+ [170]. 
Furthermore, Nrf2 has been shown to regulate the production of microglial biofactors [171]. 
Thus, in future studies, it is essential to address the functions of microglial IL-6 and the 
regulatory effect of Nrf2 in response to MeHg treatment.   
 
On the other hand, microglial activity can be modulated by other cell types in the brain. Neurons 
can increase microglial reactivity [172]. Co-culturing with neurons leads microglial cells to 
differentiate to a macrophagic state, which suggests certain diffusible factors released from 
neurons could result in the activation of microglial cells [173]. In contrast to neurons, astrocytes 
appear to dampen microglial reaction. The current study was performed in purified microglial 
cells after acute MeHg treatment, given the cross-talk between the various cell types. It is 
imperative to extend the findings regarding MeHg’s function on microglial cells to more 
complex cellular networks, such as co-cultures and, ultimately, to in vivo preparations.  
  
In summary, our work demonstrates that microglial cells are the first CNS cell type to respond to 
MeHg. Future studies on either the attenuation of intracellular ROS generation or the 
upregulation of GSH and Nrf2 in microglial cells could afford potential therapeutic value and 
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more efficacious treatment techniques and protocols to address and ameliorate MeHg poisoning 
at early stages of exposure.  
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CHAPTER III 
 
COMPARATIVE STUDY ON THE RESPONSE OF RAT PRIMARY ASTROCYTES 
AND MICROGLIAL CELLS TO METHYLMERCURY TOXICITY 
 
This chapter has been published as an article under the title as  
“Comparative study on the response of rat primary astrocytes and microglia to methylmercury 
toxicity” 
In Glia. 2011 May;59(5):810-20 
 
Summary 
As two major glial cell types found in the brain, astrocytes and microglial cells play pivotal and 
yet differential roles in maintaining normal brain functions. Even though both cell types been 
implicated as major targets of methylmercury (MeHg), their sensitivity and adaptive response to 
MeHg can vary given their distinctive properties under physiological conditions. This study was 
carried out to compare the response of astrocytes with microglial cells upon MeHg treatment, in 
order to delineate their different roles in mediating MeHg neurotoxicity. The study addressed the 
effects of MeHg on their cell viability, reactive oxygen species (ROS) generation and glutathione 
(GSH) levels. Results showed that microglial cells are more sensitive than astrocytes to MeHg 
treatment, consistent with higher mercury concentration, but lower basal GSH level in microglial 
cells, compared to astrocytes. Furthermore, NF-E2-related factor 2 (Nrf2), a major regulator of 
intracellular antioxidant response and its downstream genes were upregulated in both cells, but 
with notably different kinetics.  In summary, microglial cells and astrocytes exhibit distinct 
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sensitivity to MeHg treatment, which contributes to their differential temporal adaptive responses 
to MeHg toxicity. 
 
Key words: methylmercury, microglial cells, astrocytes, reactive oxygen species, glutathione, 
Nrf2.  
 
Introduction  
Mercury, a global pollutant, is methylated to MeHg  in the aquatic environment by sulfate-
reducing bacteria [174]. It is then rapidly taken up by living organisms and biomagnified through 
the food chain, reaching concentrations 10,000-100,000 times greater in fish than in the water 
[175]. MeHg accumulates at higher concentration in fish-eating populations [176, 177]. 
Congenital Minamata disease is the most well-documented neurological disorder caused by 
MeHg poisoning [178].  
 
MeHg readily crosses the blood-brain barrier via the L-type large neutral amino acid transporter 
and distributes in all brain cell types [32]. The majority of studies on MeHg-induced central 
nervous system (CNS) damage focused on its effects on neurons [121, 179]. Recently, the 
mechanisms of MeHg neurotoxicity have been extended to other CNS cell types, predominately 
glial cells [180, 181]. Glial cells, including astrocytes and microglial cells, are not electrically 
excitable [182], however, they have diverse and important functions, such as providing support 
and nutrition [1], maintaining CNS homeostasis [103], removing pathogens [183], inducing 
neuronal differentiation [184] and mediating CNS immune responsiveness [185, 186]. 
Dysfunction of glial cells has been reported to contribute to MeHg-induced brain damage [107, 
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187]. MeHg causes ROS generation in astrocytes due to the disruption of cellular redox 
homeostasis [107]. Furthermore, MeHg inhibits astrocytic glutamate uptake, while stimulating 
glutamate efflux [90], which result in excessive glutamate in the extracelluar milieu and 
subsequent neuronal excitotoxicity. Microglial cells are the first known activated cells under 
various pathological conditions, such as inflammation, infection, trauma and degenerative 
diseases [165]. This activation and the consequent free radical generation were also observed 
after MeHg treatment [144, 187-189]. In the active state, microglial cells  release 
proinflammatory cytokines, including interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α) and 
prostaglandin E2 (PGE2), all of which influence neighboring cells [190]. Given the fact that glial 
cells are critical in maintaining CNS homeostasis and different glial cells have distinct functions, 
it was deemed important to test the hypothesis that glial subtypes will respond in distinct 
temporal manner in response to MeHg treatment.   
 
As a key protective factor against oxidative stress, Nrf-2 was found to be upregulated in both 
astrocytes and microglial cells upon MeHg treatment [153, 187]. Nrf2 is bound to Kelch-like 
ECH-associating protein 1 (Keap1) in the cytoplasm under physiological conditions [129]. The 
interaction between Nrf2 and Keap1 is disrupted upon oxidative stress and the unbound Nrf2 is 
more resistant to proteasomal degradation [191]. Accordingly, de novo Nrf2 is built up within the 
cells, leading to increased translocation of Nrf2 into nuclei [133]. Once in the nucleus, Nrf2 
interacts with antioxidant response element (ARE) to initiate the transcription of target genes, of 
which the protein products are used to detoxify xenobiotics and endogenous reactive 
electrophiles [136-138]. Accordingly, the study was designed to study differences in the kinetics 
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of Nrf2 activation in glial cell subtypes in order to gain better understanding on their respective 
roles in mediating adaptive responses to MeHg treatment.  
 
Although some previous studies have assessed the effects of MeHg on microglial cells and 
astrocytes [107, 187], they did not systemically compare the responses between astrocytes and 
microglial cells after MeHg treatment. We hypothesized that even though common factors and 
pathways are shared by astrocytes and microglial cells in response to MeHg toxicity, their 
sensitivity and regulation kinetics might differ, therefore allowing astrocytes and microglial cells 
to play different roles in mediating MeHg toxicity. Our data supported this hypothesis by 
showing that microglial cells are more sensitive than astrocytes to MeHg as measured by cell 
viability, reactive oxygen species (ROS) generation, glutathione depletion and Nrf2 activation.  
 
Experiment Procedures 
Cell Culture 
Primary astrocytes and microglial cells were isolated from postnatal day-1 neonatal Sprague-
Dawley rats, according to a published protocol [187, 192]. The mixed glial cell culture was 
maintained in minimum essential medium (MEM) (Invitrogen, Carlsbad, CA, USA), 
supplemented with 5% heat-inactivated fetal bovine serum (Hyclone, South Logan, Utah, USA) 
and 5% horse serum (Invitrogen, Carlsbad, CA, USA). After two weeks in culture, microglial 
cells and astrocytes were separated by gentle shaking for 20 min at room temperature. Cells were 
then plated in 6-well plates and cultured at 37°C in a 95% air/5% CO2 incubator.  
 
MTT Assay and LDH Assay 
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The cytotoxic effects of MeHg were evaluated by 3-[4,5- dimethylthiazol-2-yl]-2,5 
diphenyltetrazolium bromide (MTT) assay (Sigma in vitro Toxicology Assay Kit, MTT based, 
M-5655, St. Louis, MO, USA) and lactate dehydrogenase (LDH) assay. 10X MTT stocking 
solution was freshly prepared by reconstituting 15mg stock MTT reagent in 3ml of OPTI- MEM 
culture media (Invitrogen, Carlsbad, CA, USA) in the absence of phenol red. After MeHg 
treatment, 10X MTT stocking solution was directly added to each well at a final concentration of 
0.5 mg/ml. The formazan crystal precipitates were dissolved by adding an equal volume of MTT 
solubilization solution (Sigma, M-8910, St. Louis, MO, USA) and gently shaking for 20 min. Its 
absorbance at 570nm was measured and the background absorbance at 690nm was also 
measured and subtracted out. Cell viability was expressed as the 570nm-690nm ratio over 
control. Culture media (50µl) after treatment were collected for LDH analysis. Fresh assay 
mixture 100µl (L2402, Sigma, St. Louis, MO, USA) was added to the culture media and 
incubated at room temperature for 30 min in dark. The reaction was terminated by adding 1/10 
volume of 1N HCL. The absorbance at 490nm was measured and the background absorbance at 
690nm was subtracted out. Cytotoxicity was expressed as 490nm-690nm ratio over control. 
 
Detection of intracellular ROS formation  
Astrocytes and microglial cells were pre-incubated with dichlorodihydrofluorescein diacetate 
acetyl ester (H2DCFDA) (C6827, Invitrogen, Carlsbad, CA, USA) at a concentration of 25 M 
for 30 min at 37C. MeHg was added without aspirating H2DCFDA solution. After treatment as 
indicated, cells were washed with 4°C PBS twice and then precipitated at 400x g. The cell pellets 
were dissolved in 1% Triton X- 100 (Promega, Madison, Wisconsin, USA). Fluorescence was 
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measured at 530nm (excitation of 480nm) by SpectraMax M5 (Molecular Devices, Sunnyvale, 
CA, USA). The fluorescence units were plotted in the graph. 
 
Measurement of GSH 
The intracellular GSH concentration was measured by high-performance liquid chromatography 
(HPLC) as previously described [153, 187]. Cells were derivatized with iodoacetic acid and 
dansyl chloride. HPLC analysis was carried out with a propylamine column (YMC Pack, NH2, 
Waters, Milford, MA, USA) and an automated HPLC system (Alliance 2695, Waters 
Corporation, Milford, MA, USA). GSH and GSSG concentrations were normalized to the protein 
concentration of the samples analyzed with the BCA Protein Assay Reagent (23225, Thermo, 
Rockford, IL, USA).    
 
Immunocytochemistry 
Astrocytes and microglial cells were cultured on coverslips coated with poly-L-lysine. 
Immunocytochemistry was performed using the published protocol [187]. Cells were incubated 
for 1h with 1:200 rabbit anti-Nrf2 (Abcam 31136, Cambridge, MA, USA) before incubation with 
1:400 secondary antibody, donkey anti-rabbit IgG conjugated with fluorescein 
isothiocyanate FITC (Millipore, AP182F, Billerica, MA). Coverslips were mounted with 
Vectashield Mounting Medium with Propidium Iodide (PI) (VECTOR, H-1300, Burlingame, 
CA, USA). The fluorescence signal was detected using a Zeiss confocal microscope (LSM 510, 
Zeiss, Dublin, CA, USA) at the following settings: detector gain 900, amplifier offset -0.085 and 
pinhole 98. The propidium iodide (PI) signal was detected with the following settings: detector 
gain 844, amplifier offset -0.068 and pinhole 110.  
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Western Blot Analysis 
Total cellular proteins were prepared in radioimmunoprecipitation assay (RIPA, R0278-50ML, 
Sigma, St. Louis, MO, USA) buffer with protease inhibitor (Complete Protease Inhibitor 
Cocktail, 04693116001, Roche, Indianapolis, IN, USA) and Halt Phosphatase Inhibitor 
Cocktails (78427, Thermo Scientific, Rockford, IL 61105). Western blot analysis was conducted 
with primary antibodies, rabbit-anti Nrf2 (1:400) (sc- 722, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) and mouse anti β-actin (1:2,000) (A1978, Sigma, St. Louis, MO, USA). 
Secondary antibodies were donkey anti-rabbit IgG conjugated with horseradish peroxidase 
(HPR) (1:1000) (W4011, Promega, Madison, Wisconsin, USA ) and donkey anti-mouse IgG 
conjugated with horseradish HPR (1:4,000) (W4021, Promega, Madison, Wisconsin, USA). The 
density of the Nrf2- specific bands was normalized to β-actin.  
 
Quantitative Real-Time PCR 
The transcription levels of heme oxygenase 1 (Ho1), NAD(P)H dehydrogenase, quinone 1           
( Nqo1) and x- C-type transporter (xCT) were measured by real-time PCR using the Universal 
Probe Library (Roche, Indianapolis, IN, USA). Table 1 lists the primer sequences and UPL 
probes. Average threshold cycle (ΔCt) values were used to determine the relative difference 
between control and treated samples. All data were normalized to -actin levels.  
 
Table 1 
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Nrf2 Knockdown by Small Hairpin RNA (shRNA)  
At ~50-60% confluence, primary astrocytes and microglial cells were infected with 15µl 
lentiviral particles containing 1X106 infectious units of virus (IFU) for 24 hours before MeHg 
treatment. The lentiviral particles containing expression constructs of specific shRNA against 
Nrf2 (sc-37049-V, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used to knock down 
Nrf2. Lentiviral particles containing scrambled shRNA sequence with no known gene target (sc-
108080, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as the negative control.  
 
Measurement of Intracellular Mercury Level 
14C-MeHg (82 nCi/μg Hg, American Radiolabeled Chemical, Inc., St. Louis, MO) was added 
into regular MeHg at the volume ratio of 1:1,000. Cells were maintained in 6-well plates and 
treated with radiolabeled 14C-MeHg/“cold” MeHg mixture at concentrations indicated. At the 
end of the treatments, cells were washed three times with a cold mannitol buffer [290 mM 
mannitol, 10 mM Tris nitrate and 0.5 mM calcium nitrate (Ca(NO3)2] and lysed with 1M sodium 
hydroxide. Cell lysates (750 μl) were combined with 75 μl 10 M HCl, and radioactivity was 
measured in a liquid scintillation counter (Tri-Carb 2900TR, Perkin Elmer Life Science). For 
each well, radioactivity was corrected for cellular protein content determined by the BCA assay.  
 
Statistical analysis 
All results were expressed as means ± standard errors. Unless otherwise specified, differences 
among treatment groups were analyzed by one-way analysis of variance (ANOVA), followed by 
Bonferroni’s post hoc test. Statistical significance was set at p<0.05. All experiments were 
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repeated with at least three independently isolated cell cultures, and data analysis was carried out 
with GraphPad Prism (GraphPad Software, San Diego, CA, USA).  
 
 
Results 
Microglial Cells Are More Vulnerable to MeHg Compared with Astrocytes 
As a first step, we compared the vulnerability of primary microglial cells and astrocytes in 
response to MeHg. Either cell type was treated for 6 h with MeHg and viability was determined 
by the MTT and LDH assays. The absorbance of MTT (570nm) is positively correlated with cell 
viability [193, 194].  
 
As shown in Fig.12, MeHg (≥ 1µM) caused a significant decrease (p<0.05) in microglial cell 
viability. In contrast, the same treatment in astrocytes did not lead to significant cell death. A 
positive control, 100µM H2O2 treatment reduced cell viability to 24±0.08% (p<0.001) and 
66.8±5.3% (p<0.001) of controls in microglia and astrocytes, respectively. The absorbance of 
LDH (490nm) is reversely correlated with cell viability [195]. Microglial LDH absorbance was 
significantly increased after 1µM (p<0.01) and 5µM (p<0.001) MeHg treatment for 6h, while 
MeHg (up to 5µM) did not cause a significant increase in LDH absorbance in astrocytes 
(Fig.13). These results are consistent with the MTT assay results (Fig.12) reflecting increased 
rate of cell death in microglia vs. astcocytes. 
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Fig 12 
 
 
Fig12. MTT assay result of astrocytes and microglial cells. Effects of MeHg cytotoxicity on 
astrocytes and microglial cells were measured by MTT assay after MeHg treatment for 6 hours. 
MeHg at 1 and 5µM caused a decrease in cell viability in microglial cells. In contrast, MeHg up 
to 5µM did not decrease astrocyte viability. 100µM H2O2 was used as a positive control. Values 
are expressed as the mean±SEM derived from three independent experiments. 
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Fig 13 
 
Fig 13. LDH assay result of astrocytes and microglial cells. Effects of MeHg cytotoxicity on 
astrocytes and microglial cells were measured by LDH assay after MeHg treatment for 6 hours. 
The results showed 1 and 5µM MeHg treatment significantly increased the number of damaged 
microglial cells, but not astrocytes. Only 100µM H2O2, the positive control, resulted in increased 
number of damages astrocytes. Values are expressed as the mean±SEM derived from three 
independent experiments. 
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Microglial Cells and Astrocytes Exhibit Distinct Kinetics and Levels of ROS Generation 
To explain the difference in cell vulnerability (Figs. 12 and 13), we tested whether the kinetics 
and levels of ROS generation, a common cause of cell death, differed between astrocytes and 
microglial cells. The H2DCFDA based assay was used to measure intracellular ROS. Lipophilic 
H2DCFDA diffuses freely through the cell membrane and converted to hydrophilic 2',7'-
dichlorofluorescin (DCF) intracellularly [196]. Once in the cell, DCF reacts with ROS and 
fluoresces, providing a tool for measuring intracellular ROS. As shown in Fig. 14, increased 
ROS levels in microglial cells were detected as early as 1min after 5µM MeHg treatment 
(222.6±39.01, p<0.01) or 100µM H2O2 treatment (229.03±40.08, p<0.01). . ROS continued to 
rise to 243.11±15.25 (p<0.01) of control at 1µM MeHg and 298.45±40.30 (p<0.001) at 5 µM 
MeHg treatment for 10min. MeHg treatment at 5µM for 1h increased ROS to 338.99±28.92 
(p<0.001) of control.  In astrocytes, however, the increase in ROS generation was only observed 
after 5µM MeHg treatment for 6h.  
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Fig 14 
 
Fig 14. ROS production in astrocytes and microglial cells. DCF fluorescence was measured 
1min, 10min and 1h after MeHg was added in both cell types, and 6 hour treatment data were 
only collected in astrocytes. The increased ROS level in microglial cells was first detected at 
1min in 5µM MeHg treatment group. Higher MeHg concentration and longer treatment time led 
to more ROS generation in microglial cells. In astrocytes, however, only 5µM MeHg treatment 
for 6h increased intracellular ROS level. Astrocytes had constantly lower ROS level than 
microglial cells after the same treatment. H2O2 at 100µM was used as positive control. Values 
are expressed as the mean±SEM derived from six independent experiments.  
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MeHg Causes Rapid GSH Reduction in Microglial Cells, but not in Astrocytes 
GSH detoxifies ROS and in the process generates GSSG, the oxidized form of GSH [197]. Given 
the different kinetics in ROS production in astrocytes and microglial cells (Fig. 14), additional 
studies were carried out to compare the GSH levels in the two cell types in response to MeHg 
treatment. The GSH/GSSG ratio of the control group was standardized to 100% (Fig. 15). MeHg 
(1µM and 5µM) treatment for 1min decreased the microglial GSH/GSSG ratio to 69.01±16.9% 
(p<0.05) and 51.32±20.9% (p<0.01) of control levels. A further reduction in the microglial 
GSH/GSSG ratio was observed after longer MeHg treatment (for 10min and 1h) in a 
concentration- and time-dependent manner. In contrast, a reduction in the astrocytic GSH/GSSG 
ratio was not detected until 6 h after treatment with 5µM MeHg treatment (p<0.01).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 73 
 
Fig 15 
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Fig 15. GSH/GSSG ratios in microglial cells and astrocyters. GSH and GSSG concentrations 
were measured by HPLC and the ratios of GSH/GSSG were calculated. The ratio of control 
group was set to 100% and each treatment group was compared with its corresponding control 
level and the percentage of control was used to plot the graph Both cell types were treated with 
MeHg at concentrations indicated in the graph for 1min, 10min and 1h. Only astrocytes were 
treated for 6h. . The results demonstrated that MeHg caused acute and robust reduction in 
microglial GSH/GSSG ratio in a concentration-dependent manner. In contrast, only 5µM MeHg 
treatment for 6h caused reduction in GSH/GSSG ratio in astrocytes. Values are expressed as the 
mean±SEM derived from three independent experiments. 
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Kinetic profiles of Nrf2 Upregulation differ between Microglial Cells and Astrocytes 
Nrf2 plays a pivotal role in maintaining the redox balance upon MeHg treatment [153, 187]. 
Given the differences in ROS generation (Fig. 14) and GSH reduction (Fig. 15) after MeHg 
treatment in astrocytes vs. microglial cells, additional studies were performed to determine if 
Nrf2 kinetics showed a cell-specific signature. The upregulation of Nrf2 protein level and its 
nuclear translocation were detected by confocal microscopy.  
 
As shown in Fig. 16A, the basal level of Nrf2 (green fluorescence) was low in both cell types. 
After 10min treatment with 0.1µM MeHg, Nrf2 fluorescence was sparsely detected in microglial 
cells, but a higher MeHg concentration (≥1µM), appreciably increased the Nrf2 fluorescence 
intensity and promoted its nuclear translocation, as indicated by the colocalization of Nrf2 
(green) and PI staining (counterstaining nuclei in red). In contrast, changes in Nrf2 fluorescence 
intensity and nuclear translocation were observed in astrocytes only at a much later time point 
(after 6-hour treatment) and only at the highest MeHg concentration (5µM) of MeHg (Fig 16B). 
Consistent with the profile of ROS generation (Fig. 14) and GSH reduction (Fig. 15), these data 
suggest that changes in Nrf2 protein level in astrocytes occur on a more protracted time-scale 
compared to microglial cells.  
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Fig 16 
16A 
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16B 
 
 
 
Fig 16 Immunostaining of Nrf2 in microglial cells and astrocytes. Nrf2 was labeled in green and 
cell nuclei were stained by PI dye in red. (A) In microglial cells, control group showed minimal 
Nrf2 in the cytosol. MeHg treatment at 0.1µM  for 10min increased Nrf2 in the cytosol but not in 
the nuclei. Higher concentration of MeHg increased Nrf2 in both cytosol and nuclei. Yellow 
color indicated the colocalization of Nrf2 and DNA in microglial nuclei. (B) In astrocytes, only 
5µM MeHg treatment for 6h increased Nrf2 in both cytosol and nuclei. Photographs show 
representative fields observed from four independent experiments.  
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Changes in microglail and astrocytic Nrf2 fluorescent intensities (Fig. 16) were also corroborated 
by means of western blot analysis. As shown in Fig. 17, MeHg treatment in microglial cells 
caused a concentration- and time-dependent increase in Nrf2. However, in astrocytes, Nrf2 
remained unchanged after 1h MeHg treatment at all three concentrations tested (0.1~5 µM). 
After prolonged MeHg treatment (6h), MeHg only at 5µM appreciably increased astrocytic Nrf2 
protein level (P<0.05).  
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Fig 17 
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Fig 17.  Nrf2 protein level in the whole cell lysate of microglial cells and astrocytes. The Nrf2 
protein level in whole cell lysate was measured by western blot. Both cell types were treated 
with MeHg at concentrations indicated in the graph for 1min, 10min and 1h. Only astrocytes 
were treated for 6h. Nrf2 protein level increased in microglial cells commencing at 1min into 1 
and 5µM MeHg treatment. After 10min MeHg treatment, MeHg ≥ 0.1µM increased Nrf2 protein 
level in microglial cells and the increase remained after 1h MeHg treatment. However, in 
astrocytes, only 5µM MeHg treatment for 6h increased Nrf2 protein level.. Values are expressed 
as the mean±SEM derived from three independent experiments. 
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The Temporal Upregulation of Nrf2 Downstream Genes Differs in Microglial Cells vs. 
Astrocytes 
Based on the changes noted above (Figs. 16, 17), microglial cells were treated for 30 min, while 
astrocytes were treated for 6h with MeHg before the mRNA was harvested for real-time PCR 
analysis. As shown in Fig. 18A, in microglial cells, the transcription levels of Ho1 and Nqo1 
were upregulated in response to 1 and 5µM MeHg treatment. xCT gene expression was increased 
by 2.3±1.46 fold over the control value (p<0.01) after 5µM MeHg treatment for 30min. In 
contrast, the increased transcription levels of these genes in astrocytes were detected only after 
MeHg treatment at highest concentration (5µM) for 6h (Fig 18B).  
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Fig 18 
18A 
 
 
18B  
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Fig 18. The expression of Ho1, Nqo1 and xCT in microglial cells and astrocyts. Gene expression 
level was measured by real-time PCR. The differences in the average threshold cycle (ΔCt) 
values were determined and normalized to the expression of β-actin. (A) Microglial cells were 
treated for 30min. The transcription levels of Ho1 and Nqo1 were upregulated in response to 
MeHg treatment at 1 and 5µM. xCT gene expression was increased after 5µM MeHg treatment. 
(B) Astrocytes were treated with MeHg for 6 hours. The increased transcription levels of these 
genes in were detected only after MeHg treatment at highest concentration (5µM) for 6 hours.  
Values are expressed as the mean±SEM derived from three independent experiments. 
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Next, we tested the hypothesis that the transcriptional upregulation of these genes was dependent 
upon Nrf2 activity. Nrf2 activity was inhibited by knocking down Nrf2 gene expression with 
shRNA. As shown in Fig. 19A, 5µM MeHg treatment for 30min resulted in a significant increase 
in Ho1 mRNA levels in both uninfected and scramble shRNA-infected microglial cells (p<0.05) 
compared with controls. In contrast, microglial cells’ Ho1 transcription level of Nrf2 knockdown 
was indistinguishable from control levels.  Similar changes in microglial Nqo1 and xCT were 
also observed after Nrf2 knockdown (Fig. 19A). In astrocytes (Fig. 19B), 5µM MeHg treatment 
for 6 h caused a significant increase in Ho1 and Nqo1 mRNA levels in both uninfected and 
scramble shRNA infected astrocytes. Nrf2 knockdown in astrocytes brought down their 
transcription to control level. Interestingly, Nrf2 knockdown in astrocytes decreased xCT 
transcription level compared to the uninfected or scramble shRNA infected cells, but it remained 
significantly higher than in the controls (p<0.05).  
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Fig 19 
19A 
 
19B 
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Fig 19. The effect of Nrf2 knockdown on Ho1, Nqo1 and xCT expression in microglial cells and 
astrocytes. Both cell types were first infected with lentivirus as indicated for 24h and then treated 
with 5µM MeHg for 30min in microglial cells and 6h in astrocytes. The uninfected cells without 
MeHg treatment were used to measure basal gene expression level. mRNA levels of Ho1, Nqo1 
and xCT were measured by real-time PCR. The difference in the average threshold cycle (ΔCt) 
values was determined and normalized to the expression of β-actin. (A) Microglial cells treated 
with Nrf2-specific shRNA showed no significant increase in downstream gene expression as 
compared basal expression level. (B) In astrocytes, the expression of Ho1and Nqo1 from Nrf2 
knockdown group showed no signicant increase as compared to basal expression level. Even 
though xCT was upregulated in Nrf2 knockdown group, its increase was less than that of 
uninfected and random shRNA infected groups after MeHg treatment. Values are expressed as 
the mean±SEM derived from three independent experiments. 
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Nrf2 Protects Microglial Cells and Astrocytes against MeHg Toxicity  
To further evaluate the cytoprotective function of Nrf2 against MeHg-induced cell death, we 
assessed cell viability upon MeHg treatment in Nrf2 knockdown cells. As shown in Fig. 20, 
compared to uninfected microglial cells in the absence of MeHg treatment, both in uninfected 
cells and random virus infected cells, 5M MeHg treatment for 6h caused a significant decrease 
in cell viability (P<0.001) (assessed by the MTT assay). Notably, Nrf2 knockdown further 
decreased cell viability after the same treatment (p<0.001). In astrocytes, MeHg (5M) treatment 
for 6h did not significantly reduce cell viability in either uninfected cells or random virus 
infected cells. However, Nrf2 knockdown caused a significant decrease (P<0.001) in astrocyte 
viability after the same treatment.  
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Fig 20 
 
 
 
Fig 20. The effect of Nrf2 knockdown on cell viability in microglial cells and astrocytes. Cell 
viability was assessed by MTT assay. Both cell types were first infected with lenvivirus for 24h 
and then treated with 5µM MeHg for 6h. The uninfected cells without MeHg treatment were 
used to measure the maximal cell viability. The results demonstrated Nrf2 knockdown caused 
significant further reduction of cell viability in both microglial cells and astrocytes as compared 
to uninfected and random shRNA infected groups after MeHg treatment. Values are expressed as 
the mean±SEM derived from three independent experiments. 
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Astrocytes and Microglial Cells Show Differences in Intracellular Mercury Concentration 
and GSH Level   
To further address the distinctive vulnerabilities of microglial cells vs. astrocytes in response to 
MeHg treatment, next, we measured intracellular mercury (Hg) concentration and basal level of 
GSH in each cell type. The intracellular Hg concentration was measured using 14C-MeHg (refer 
to Methods for details). As shown in Fig 21, MeHg (≥1µM) treatment in microglia led to a 
significant increase in Hg accumulation within 1min of its addition to the medium (1µM, p<0.05; 
5µM, p<0.01). Notably, the intracellular microglial Hg concentration reached its peak after 5µM 
MeHg treatment for 1h. In contrast, astrocytic Hg concentration remained unchanged after 
0.1µM and 1µM MeHg treatment for up to 6 hours. Only the highest concentration of MeHg 
(5µM) increased the intracellular Hg concentration, commencing at 10min. Notably, the 
intracellular Hg concentration in astrocytes at each time point was significantly lower vs. 
microglial cells (p<0.01).  
 
As noted above, MeHg caused rapid GSH reduction (Fig. 15) and ROS production (Fig. 14) in 
microglial cells, but not in astrocytes. Given that GSH is the major detoxifying molecule of free 
radicals, we tested if microglial cells have a reduced GSH pool (vs. astrocytes) to cope with the 
increased intracellular levels of MeHg (Fig. 21) and ROS generated by MeHg treatment. The 
intracellular basal level of GSH was measured by HPLC (see Methods for details). As shown in 
Fig. 22, the basal GSH level in microglial cells was 26.71±3.85 nmol/mg protein, which was 
significantly lower than that in astrocytes (93.43±16.62 nmol/mg protein) (p<0.001).  
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Fig 21 
 
 
 
 91 
 
Fig 21. Intracellular mercury concentration in microglial cells and astrocytes. Both cell types 
were treated with the mixture of 14C-MeHg and non-radioactive MeHg (volume ratio of 1:1000) 
at concentrations indicated in the graph for 1min, 10min, 1h and 6h. The radioactivity was 
measured and intracellular mercury level was calculated and normalized to protein concentration. 
The results showed that 1µM and 5µM MeHg treatment increased intracellular mercury 
concentration in microglial cells at all time points in a concentration-dependent manner. MeHg 
up to 1µM failed to change intracellular mercury concentration in astrocytes within 6h. Only 
5µM MeHg treatment increased intracellular mercury concentration in astrocytes commencing at 
10min into treatment. Notably, astrocytes had constantly lower intracellular mercury level than 
microglial cells. Values are expressed as the mean±SEM derived from three independent 
experiments. 
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Fig 22 
 
 
 
 
Fig 22. The basal level of intracellular GSH in microglial cells and astrocytes. GSH level was 
measured by HPLC. The result showed almost four-fold higher GSH level in 
astrocytes(93.43±16.62nmol/mg protein) than that in microglial cells (26.71±3.85 nmol/mg 
protein). Values are expressed as the mean±SEM derived from three independent experiments.  
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Discussion 
To our knowledge, this is the first study to systematically compare the differences between 
primary microglial cells and astrocytes in response to physiologically relevant MeHg treatments. 
The concentrations of MeHg (0.1-5µM) used in this study well represent the common brain 
MeHg level as reported by Akagi et al. [151]. Several measurements of responsiveness to MeHg 
established that microglial cells responded to this organometal more rapidly than astrocytes, and 
these responses occurred to inherently lower MeHg concentrations. For example, MeHg (≤1µM) 
treatment led to rapid ROS generation and GSH depletion in microglial cells commencing at 
1min after treatment, and well before the 6 h time point where similar changes were observed in 
astrocytes treated with 5µM MeHg (Figs. 14,15). Consistent with the time scale we observed, 
Long et al reported that microglial cells responded to TiO2 at ≥60ppm with a rapid (1-5min) 
release of H2O2 [156]. However, various toxins, such as 1mM dibutyryl cAMP and 1µg/ml 
Lipopolysaccharide (LPS), are reported to activate astrocytes after 6h treatment [198].  
 
MeHg, like other toxins, first stimulates microglial cells and the microglial response is not 
causative agents dependent [156]. Consistently, comparative studies carried out in cultured cells 
and animals treated with neurotoxins have shown that astrocytes are less sensitive than 
microglial cells [117, 118] and astrocytic reactions occur much later than in microglial cells 
[119, 120]. For example, in vitro experiment demonstrated that low concentration of 
neurotoxicant trimethyltin (TMT), 10-9M, activates microglial cells. However, at least 10 folds 
higher concentration of TMT is required to stimulate astrocytes [118]. Furthermore, in vivo 
experiment showed that reactive microglia in rat brain were evident 2 days after TMT treatment, 
but the astrocytosis was not observed until 14 days after TMT treatment at the same 
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concentration [120]. Similarly, the activation of either glial cell types could play a different role 
in mediating MeHg neurotoxicity due to the different kinetics of their responses to MeHg. Based 
on our observation, the response of microglial cells occurred much faster than astrocytes, 
suggesting that microglial cells may participate in mediating the earlier phases of MeHg toxicity. 
Astrocytes, on the other hand, may mediate MeHg neurotoxicity on a protracted time scale.   
 
The difference in sensitivity to MeHg could allow microglial cells and astrocytes to act at 
different time windows of MeHg toxicity. Indeed, we found Nrf2 exhibited distinctive 
upregulation kinetics between these two cell types after MeHg treatment. Consistent with 
previous observations [187], the upregulation of microglial Nrf2 occurred 1min after MeHg 
treatment (Fig. 17) with Nrf2 undergoing nuclear translocation 10min post MeHg treatment. In 
contrast, these changes in astrocytes were not inherent only to the highest MeHg treatment (5µM 
MeHg), and were evident only at 6h post treatment (Figs. 16,17). Consistent with the difference 
in Nrf2 kinetics in the two cell types, the temporal expression of Nrf2 downstream genes was 
distinctively regulated in these two cell types (Figs. 18,19).  The expression of Ho1, Nqo1 and 
xCT rapidly increased in microglial cells but delayed in astrocytes (6h post MeHg treatment). As 
we confirmed the cytoprotective function of Nrf2 in both cell types by shRNA apporoach (Fig. 
20), the protective effects of Nrf2 in these two cell types are different given the truth that the 
regulatory kinetics of Nrf2 is different in microglial cells v.s. astrocytes.   
  
The earlier responsiveness of microglia vs. astrocytes to MeHg treatment was corroborated by 
distinct differences in the intracellular Hg concentrations as well as the basal GSH levels in the 
two cell types (Fig 21,22). Consistent with earlier  reports that microglial cells accumulated the 
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largest concentration of Hg following MeHg treatment in non-human primates [102], we 
observed that intracellular Hg concentration in microglial cells were significantly higher than 
that in astrocytes after the same MeHg treatment. This may reflect the faster and more robust 
response of microglial cells vs. astrocytes to MeHg. Previous studies have established the 
cytoprotective effects of GSH in MeHg-induced toxicity [159, 160]. GSH readily binds to MeHg 
via its sulfhydryl groups, and the conjugated products are actively pumped out of the cells by 
multidrug resistance proteins, leading to a decrease in intracellular MeHg and its toxicity [161]. 
In addition, GSH detoxifies ROS generated by MeHg to maintain the redox balance in the cell 
[199]. As shown in Fig. 22, a greater than four folds higher basal GSH level were noted in 
astrocytes compared to microglial cells, which may explain the more rapid changes in ROS 
levels and GSH/GSSG ratio in microglial cells, where GSH would be expected to be depleted 
more rapidly given its lower basal levels. It may also reflect the delayed Hg accumulation and 
lower intracellular Hg level in astrocytes as higher GSH levels may facilitate the extrusion of the 
metal from these cells vs. microglia (Fig.21).    
 
MeHg not only directly activates glial cells, but also alters normal CNS function via molecules 
released by glial cells. For example, upon activation, microglia produce free radicals (Figs. 14, 
15)[156] and release proinflammatory cytokines such as interleukin 6 (IL-6) [155]. Microglial 
cells have been shown to influence other cell types via IL-6 secretion. For example, it induces 
astrogliosis associated with MeHg-induced microglial clusters [143]. Interestingly, as a 
proinflammatory factor, IL-6 may have a neuroprotective function. IL-6 co-administered with 
MeHg prevented MeHg-induced degeneration of the neuronal cytoskeleton [143]. Similar 
protective effects of IL-6 against the toxic effects of glutamate have also been previously 
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described [169]. In contrast, astrocytic dysfunction might mediate MeHg toxicity at later stages. 
For example, Yin et al. reported that the disrupted amino acid homeostasis plays the critical role 
in astrocytes- mediated MeHg toxicity [200]. Among these amino acids, glutamate is profoundly 
affected [200]. MeHg inhibits astrocytic glutamate uptake, while stimulating glutamate efflux 
[90], consequently resulting in an excessive concentration of synaptic glutamate, which 
ultimately leads to neuronal excitotoxicity and cell death [147]. Astrocytes also appear to 
dampen microglial activation under physiological conditions [173]. Therefore, MeHg-induced 
astrocytic dysfunction may hasten microglial dysfunction by removing astrocytic inhibitory 
function.  
 
In summary, results presented herein demonstrated the different response kinetics of astrocytes 
and microglial cells to MeHg treatment. Microglial cells exhibited a faster and more robust 
response to MeHg compared to astrocytes. The microglial response to MeHg reflects a 
significantly greater accumulation of Hg in these cells vs. astrocytes, as well as lower basal GSH 
pool to detoxify ROS generated by MeHg and possibly direct binding to MeHg itself. 
Collectively, these studies suggest that microglial cells and astrocytes assume different role on a 
protracted time-scale, with microglia representing the early responders and astrocytes assuming a 
similar role later on upon treatment. A better understanding of the distinctive roles of these cells 
in mediating MeHg toxicity under in vivo conditions is clearly warranted, as it may facilitate 
potential therapeutic modalities to ameliorate MeHg-induced CNS damage.  
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CHAPTER IV  
 
CONCLUSION AND DISCUSSION 
 
To our knowledge, this is the first study to investigate the response of primary astrocytes and 
microglia to acute MeHg exposure, as well as to compare responses in glial cell types upon 
treatments with physiologically relevant concentrations of MeHg. Furthermore, the protective 
functions of Nrf2 and its downstream genes in both astrocytes and microglia have been 
systematically studied. As stated above, some previous studies [144] were carried out to study 
glial response to MeHg treatment, but the concentrations used in those studies were higher than 
the concentrations of MeHg (0.1-5µM) used in my studies which are within the range of brain 
MeHg levels in human pathological conditions as reported by Akagi et al. [151]. The majority 
cell lines used in previous studies are cancer- derived immortalized glia [143, 144], whose 
response may not represent the “normal” glia. More importantly, I compared the kinetics of 
microglial response with astrocytic response after MeHg treatment by using the cells harvested 
from the same animals, which minimized the individual variations.    
 
In the first part of my thesis project, we have demonstrated that MeHg leads to rapid ROS 
generation and GSH depletion in primary microglia commencing at one minute post MeHg 
exposure. Previous studies have reported an increase in ROS in microglial cells after prolonged 
MeHg treatment at higher concentrations [143, 144, 155]. However, these studies do not capture 
the acute microglial response to lower concentrations of MeHg as detected in early stages of 
Minamata disease patients.  Notably, the primary cell culture used in my project best represents 
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the vulnerability of developing brains since all cells were harvested from 1-day-old neonatal rats. 
As stated above, the developing glial cells are more sensitive to MeHg poisoning, and therefore, 
the cell culture I used in my project is the best model system since it fills in the gap missed by 
previous studies using glial cell cultures after multiple passages. Here, we have revealed that 
5M MeHg treatment causes a significant increase in ROS generation in primary microglial cells 
commencing at one minute post MeHg exposure.  The acute response of microglia appears to be 
independent to the stimuli, since the similar acute ROS generation in microglial cells was also 
observed after TiO2 exposure [156].  
 
In the second part of my thesis project, I compared the difference in the kinetics of microglial 
response to that of astrocytes after MeHg treatment. The two major glial cell types in the brain, 
astrocytes and microglia play pivotal yet different roles in maintaining optimal brain function. 
Comparing to microglia, astrocytes also produce excessive ROS in response to MeHg treatment, 
but it is only detected after much longer exposure to MeHg (6 hours) (Fig 14), which is 
consistent with previous reports [107, 153]. Our data clearly suggest that microglia are the first 
line of cellular response to MeHg poisoning in the CNS. Supporting this notion, comparative 
studies in cultured cells treated with trimethyltin (TMT) found significantly greater sensitivity in 
microglia compared to astrocytes [117, 118]. A low in vitro concentration of TMT (10-9M) led 
to microglial activation, while at least a 10-fold higher concentration was required for the 
activation of astrocytes [118]. As mentioned above, even though both cell types have been 
implicated as major targets of MeHg, their unique sensitivities and adaptive responses to this 
metal can vary given their distinctive properties and physiological functions.  Thus, the distinct 
sensitivities of microglia and astrocytes likely indicate different roles for the two cell types along 
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a temporal axis in response to MeHg. Accordingly, the second part of thesis project was carried 
out to compare the respective responses of astrocytes and microglia following treatment with 
MeHg, examining and addressing the effects of MeHg on cell viability, reactive oxygen species 
(ROS) generation and glutathione (GSH) levels, as well as mercury (Hg) uptake and the 
expression of NF-E2-related factor 2 (Nrf2).  
 
In mammalian cells, GSH:GSSG balance is dynamically maintained stable. GSH is used to 
detoxify ROS and itself is converted to the oxidized form, GSSG. As my data showed, ROS in 
microglia and astrocytes are increased in response to MeHg treatment (Fig 4, 5, 14) and, 
correspondingly, the GSH/GSSG ratio is decreased in microglia (Fig 6) and astrocytes (Fig 15).  
The mechanism of GSH protective function has been studied extensively [159, 160].  Konig 
[161] reported that GSH binds to Hg compounds via its sulfhydryl groups, and the conjugated 
products are actively pumped out of the cells by multidrug resistance proteins (MRPs), leading to 
the decrease in intracellular Hg and its toxicity. In addition, Farina [201] and Das [199] reported 
that GSH prevents the interaction of Hg with protein thiols  and detoxifies ROS generated by 
MeHg to maintain the redox status in the cell.  
 
Previous studies revealed that lower intracellular GSH level is correlated with greater glial cell 
death. For example, Miura and Clarkson [162, 163] studied the correlation between GSH level 
and MeHg toxicity using MeHg-resistant rat pheochromocytoma PC12 cell line. Compared to 
nonresistant cells, the levels of GSH in resistant cells were four-fold higher, which led to greater 
efflux and less intracellular retention of MeHg. Consistent with previous study [202], in my 
experiments, the basal level of astrocytic GSH was measured to be 80±10nmol/mg protein [203]. 
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Compared to astrocytes, microglial GSH levels are only 25% of those in astrocytes (Fig 22), 
which likely reflects their diminished capability to buffer MeHg-induced ROS generation. Thus, 
lower GSH levels in microglial cells may lead to reduced MeHg efflux and increased 
intracellular Hg levels. This may explain previous findings of the earliest and highest 
accumulation of Hg deposits in microglial cells in the rat brain [164] and non-human primates 
[102].  Our data also show that the lower intracellular GSH level is correlated with greater glial 
cell death. In microglia, treatment with 5M MeHg causes maximal reduction in GSH levels 
(Fig 6) as well as maximal microglial death (Fig 3), which supports the notion that GSH plays a 
critical role as a protective molecule against MeHg toxicity.  
 
As shown before, microglia are more sensitive to MeHg exposure and respond much faster than 
astrocytes. It is reasonable hypothesize that the distinct sensitivities of microglia and astrocytes 
likely indicate different roles for the two cell types along a temporal axis in response to MeHg. 
Previous studies revealed that intracellular ROS generation parallel to the increase in Nrf2 
protein and it is also the pivotal molecule in regulating Nrf2 levels [153]. Consistent with the 
previous literatures, the increase in Nrf2 (Fig 8) protein levels was paralleled by the MeHg-
induced increase of ROS (Fig 4,5), as well as the decrease in GSH (Fig 6). Indeed, Nrf2 
expression exhibited distinct upregulation kinetics after MeHg treatment in microglia vs. 
astrocytes. For example, the upregulation of microglial Nrf2 occurred as early as 1 min after 
MeHg treatment at 1M (Fig. 7), however, the phenomenon was not observed in astrocytes until 
5M MeHg treatment for 6 hours. Nrf2 is the transcription factor and undergoes nuclear 
translocation [153]. In my project, I also observed Nrf2 nuclear translocation commencing at 10 
min post MeHg exposure. Our data support the new model proposed by Li et al [133], that 
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oxidative stress disrupts the interaction between Nrf2 and Keap1 leading to the decreased rate of 
proteasomal degradation of Nrf2 in cytosolic fraction. This model explains why the increase of 
cytosolic Nrf2 was detected as early as 1 min post MeHg exposure [133]. In contrast, these 
changes in astrocytes were inherent only with the highest MeHg treatment (5µM MeHg) and 
were evident only at 6 h post-treatment (Figs. 16,17). Based on the fact that Nrf2 activation in 
primary astrocytes after MeHg treatment occurred much later than microglia, our results further 
support the notion that microglia are the first glial cell type to respond to MeHg treatment[165].  
 
Nrf2 is the key protective molecule regulating its downstream antioxidant genes and the nuclear 
translocation of Nrf2 is critical for attenuation of oxidative stress [166]. It is reported that 
primary mouse hepatocytes isolated from Nrf2- deficient mice were highly susceptible to MeHg-
induced cytotoxicity, and Nrf2 overexpression can attenuate MeHg- induced cytotoxicity in SH-
SY5Y neuroblastoma cells [166]. Consistent with these studies, we also observed increased 
astrocytic and microglial death upon Nrf2 knockdown by using shRNA approach (Fig 20). 
Previous studies also confirmed the critical function of Nrf2 in orchestrating the expression of 
Ho-1, Nqo1 and xCT, all of which detoxify xenobiotics and endogenous reactive electrophiles in 
numerous cell types. For example, Nrf2 in renal epithelial cells upregulated the Nqo1 reporter 
construct after exposure to hypoxia/reoxygenation [168]. Similarly, in human lymphoma cells, 
gallium nitrate upregulated the Ho-1 mRNA level as a result of Nrf2 activation [153, 167]. Once 
I observed the difference in Nrf2 expression kinetics in microglia and astrocytes, I further carried 
out experiments to investigate the difference in temporal regulation of Nrf2 downstream genes 
(Figs. 18,19). My results clearly showed that the expression of Ho1, Nqo1 and xCT rapidly 
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increased in microglia, but the increase was delayed in astrocytes (6 h post MeHg treatment; 
Figs.18,19).  
 
Based on the combined data generated in my project, it is reasonable to conclude that the 
difference in the kinetics of ROS generation, Nrf2 activation and the upregulation of its 
downstream genes could reflect the temporal difference in the activation of these two cell types. 
Notably, the timescale of the changes is not dependent on stimuli, since it is also reported in 
earlier studies. For example, Long and colleagues reported that microglia responded to titanium 
dioxide (TiO2; ≥60ppm) with a rapid (1-5min) release of H2O2 [156]. In contrast, 1mM dibutyryl 
cAMP and 1µg/ml Lipopolysaccharide (LPS) led to astrocytic activation after 6h treatment 
[198]. The faster activation of microglia in comparison to astrocytes was also observed in vivo 
upon TMT treatment. Reactive microglia in the rat brain were noted within 2 days after TMT 
treatment, while astrocytosis was not evident until 14 days after TMT treatment [120]. From a 
molecular point of view, the differences between microglial and astrocytic responsiveness to 
MeHg appear to be related, at least in part, to differences in their respective cellular thiol 
statuses. This idea is based on three important events: (i) microglia accumulate higher levels of 
Hg (Fig. 21), which interact with and oxidize thiols; (ii) microglia contain lower GSH levels 
(Fig. 22), which maintains the normal cellular thiol status; and (iii) Nrf2 activation is regulated 
by oxidative modifications of its cysteine thiol groups, as well as by thiol oxidation in Kelch-like 
ECH-associated protein-1 (Keap1) [204]. The differential thiol status in microglia and astrocytes 
also explains the observed changes in ROS levels and the GSH/GSSG ratio during MeHg 
exposure, where microglial GSH was depleted faster given its lower basal levels. Intracellular 
MeHg has been reported to be exported out of cells as the GSH complex [205]; thus, the higher 
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basal GSH levels in astrocytes lead to delayed Hg accumulation and lower intracellular Hg levels 
in these cells (compared to microglia). 
 
As stated above, the major function of glia is to maintain the hemostasis of CNS and the 
dysfunction of glia adversely affect the normal function of brain via molecules released by these 
cells. There are numerous studies showing microglia, upon activation, release proinflammatory 
cytokines, such as interleukin 6 (IL-6) [155]. IL-6 has very complicated effects on CNS. For 
example, Eskes [143] reported that IL-6 induces astrogliosis associated with MeHg-induced 
microglial clusters. Interestingly, as a proinflammatory factor, IL-6 may have also a 
neuroprotective function. IL-6 co-administered with MeHg has been shown to prevent the 
MeHg-induced degeneration of the neuronal cytoskeleton [143]. Similar protective effects of IL-
6 against the toxic effects of glutamate have also been previously described [169].  
As shown in my results, astrocytic dysfunction might mediate MeHg toxicity at later stages. For 
example, disrupted amino acid homeostasis after MeHg treatment may ensue upon MeHg-
induced inhibition of astrocytic glutamate uptake [200] while stimulating glutamate efflux [90], 
resulting in an excessive concentration of synaptic glutamate, which ultimately leads to neuronal 
excitotoxicity and cell death [147]. As mentioned above, neurons, microglia and astrocytes form 
the complex cell-cell network, and therefore the dysfunction of one cell type affects the function 
of the other cell type. For example, Eskes [172] reported that neurons can increase microglial 
reactivity Co-culturing with neurons leads microglial cells to differentiate to a macrophagic state, 
which suggests certain diffusible factors released from neurons could result in the activation of 
microglial cells [172]. In contrast to neurons, Thomas [173] reported that astrocytes dampen 
microglial activation under physiological conditions. Notably, my thesis project was performed 
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in purified glial cells after acute MeHg treatment. Given the cross-talk between the various cell 
types, it is imperative to extend the findings regarding MeHg’s function on microglial cells to 
more complex cellular networks, such as co-cultures and, ultimately, to in vivo preparations.  
 
In summary, the results of my thesis project demonstrate different response kinetics in astrocytes 
and microglia upon MeHg treatment. Microglia exhibited a faster and more robust response to 
MeHg compared to astrocytes. The microglial response to MeHg reflects a significantly greater 
accumulation of Hg in these cells than astrocytes, as well as a lower basal GSH pool for 
detoxifying ROS generated by MeHg. The faster microglia activation of Nrf2 and its 
downstream genes (Ho1, Nqo1 and xCT) is likely related to its lower thiol status. Collectively, 
these studies suggest that microglia and astrocytes assume different roles on a protracted time-
scale, with microglia representing the early responders and astrocytes taking on a similar role at a 
later stage following MeHg treatment (see Fig 23). A better understanding of the distinctive roles 
of these cells in mediating MeHg toxicity under in vivo conditions is clearly warranted. As 
suggested by the results of my project, increasing intracellular GSH or upregulating Nrf2 are 
very promising therapeutic strategies to treat MeHg poisoning. Indeed, additional insight gained 
from future studies offers tremendous promise for the identification and development of potential 
therapeutic modalities to ameliorate MeHg-induced CNS damage.  
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Fig 23. The responses of microglia and astrocytes are summarized. The time axis is listed on the 
left. [Top panel] 1min post MeHg treatment, the MeHg concentration in microglia (pink) is 
elevated and intracellular ROS is produced, which leads to the conversion of GSH to GSSG in 
order to detoxify the excessive ROS. The elevated ROS also disrupts the NRF2-KEAP1 complex 
that results in the dissociation of NRF2. The free NRF2 is translocated into the nucleus where it 
stimulates downstream detoxifying gene expression, including Ho1, xCT and Nqo1. Notably, 
there is no astrocytic (blue) response at this time point. [Bottom panel] 6 hours after MeHg 
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treatment, there is similar cellular response observed in astrocytes. There is significant microglial 
(pink) death due to overwhelming oxidative stress and MeHg toxicity.  
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Appendix 
 
A. Book chapter: Neonatal Rat Primary Microglia: Isolation, Culturing and Selected 
Applications 
 
This chapter has been published in  
Chapter 12:Unit 12.17. 
Curr Protoc Toxicol. 2010 Feb; 
 
INTRODUCTION 
Neurons are the major cell type in the central nervous system (CNS), their unique electrical 
excitability distinguishing them from other cell types. Glial cells, including astrocytes, microglia 
and oligodendrocytes are non-electrically excitable. The term glia is derived from the Greek 
language and means “glue”. Yet glial cells have diverse functions, well beyond the original 
scope ascribed to them as being the mere glue that holds the neurons in place. They provide 
support and nutrition [1], maintain CNS homeostasis [103], form myelin [103] and participate in 
signal transmission [104, 105], just to name a few of their functions. The majority of glial cells 
are astrocytes, which are intimately involved in maintaining the extracellular milieu. Some 
selected functions of astrocytes include secretion of growth factors, release of cytokines and 
modulation of synaptic transmission by removal of neurotransmitters such as glutamate from the 
synaptic cleft. Oligodendrocytes are the myelin-forming cells in the CNS and are analogues to 
Schwann cells of the peripheral nervous system.  
 
 108 
 
Microglia comprise approximately 12% of total cell population in the brain and are the second 
largest glial cell type. Microglia are derived from myeloid lineage [113]. In postnatal rodents, 
immunocytochemical studies using antibodies to F4/80 (ERM1), CR3 and FcγRII/III establish 
that the microglia enter the brain from the circulation and are derived from circulating monocytes 
[113]. In the brain, they possess phagocytic activity and survey the parenchyma. Microglia 
express low level of Major Histocompatibility Complex (MHC-II) and function as antigen 
presenting cells (APC) of the CNS [113]. They are in close contact with other cells in the brain, 
mainly astrocytes, thus establishing cross-talk that mediates and synergizes responses both in 
physiological and pathological conditions. Under optimal conditions microglial surface 
receptors, such as TREM2 and Siglecs maintain the microglia in an inactivated state [113]. In the 
presence of inflammation, infection, trauma and degenerative diseases, microglia are the first cell 
type to become activated. Their activation is inherent to Alzheimer’s disease [114], Parkinson’s 
disease [115], HIV dementia [116] as well as numerous other pathological conditions. Once 
activated, microglia produce soluble proinflammatory cytokines, prostaglandins and interleukins, 
such as tumor necrosis factor-α (TNF-α), PGE2, interleukin-1 (IL-1) and interleukin-6 (IL-6), 
which not only contribute to the neighboring neuronal damage, but also recruit immune cells into 
the CNS.   
 
The culture technique introduced here is based on the method first published by Barger and 
Basile [206] and has undergone minor modification in our laboratory. From one litter of 1-day 
old neonatal rats (10-14 pups) we routinely get sufficient amount of mixed cells (100 millions) 
for approximately 15 225 cm2 culture flasks. These mixed cell cultures reach confluence in 
approximately 2 weeks post seeding; the culture media are changed twice weekly.  Microglia are 
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isolated from the mixed cell culture before the end of the 2nd week by gentle physical shaking 
and tapping on the flasks. After isolation, the microglia are re-seeded into three 6-well plates 
(other seeding options are possible and should be dictated by the end-points of the experiments 
you wish to conduct taking into account the numbers of replicates) with fresh culture media. The 
cell purity is routinely examined by immunohistochemistry staining for OX-42, a microglia 
specific integrin marker. In our hands, the cultures reach >95% purity. Other cells types in the 
cultures, mainly astrocytes in the mixed culture system lend the process ideal for the concomitant 
isolation of primary astrocyte cultures. These can be characterized with specific antibodies for 
intermediate skeletal proteins, such as glial fibrillary acidic protein (GFAP). The method for 
culturing and maintaining astrocytes has been previously published ([207]). 
 
The mechanical isolation protocol discussed in this chapter offers an economical method to 
isolate large amount of microglia in a short and not too labor intensive manner. Most 
importantly, it assures a high yield of cells with great reproducibility. Given the ever increasing 
importance of microglia to the field of neurotoxicology research, the ability to isolate high yield 
of primary microglia makes it possible to investigate the role and mechanisms associated with 
microglial modulation of neurotoxicity. Next, we provide a detailed description on the methods 
that is routinely used in our laboratory for the isolation and culturing of microglia, with emphasis 
on the steps which are deemed most critical for obtaining pure and healthy cultures. 
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ISOLATION AND MAINTENANCE OF PRIMARY MICROGLIAL CELL CULTURES 
MATERIALS 
Solutions and Reagents 
Coating Cell Culture Plates 
1. 70% ethanol 
2. Borate buffer 
3. Borax (71997), Sigma, 3050 Spruce St. St. Louis, MO 63103; 
4. Poly-L-lysine (P-1274), Sigma, 3050 Spruce St. St. Louis, MO 63103; 
5. Autoclaved distilled water 
6. Minimum Essential Medium (MEM) culture media, Gibco, Invitrogen, Grand Island,  
NY (11095)  
7. Minimum Essential Media, with Earle’s salts, modified for suspension cultures (S-MEM), Gibco, 
Invitrogen, Grand Island, NY (11385). 
 
Mixed Glial Cell Isolation  
1. 70% ethanol 
2. Minimum Essential Medium (MEM) culture media, Gibco, Invitrogen, Grand Island, NY 
3. Dissociation media 
4. Heat inactivated horse serum Gibco, Invitrogen, Grand Island, NY (26050070) 
5. Heat-inactivated fetal bovine serum, Gibco, Invitrogen, Grand Island, NY (10082-147). 
6. Penicillin/Streptomycin, Gibco, Invitrogen, Grand Island, NY (15140-163). 
7. Trypan blue staining solution, (T8154, Sigma) 
8. Hank's Buffered Salt Solution (HBSS), H2387, Sigma 
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9. Sigmacote® (SL-2),  Sigma, 3050 Spruce St. St. Louis, MO 63103. 
Microglia isolation 
1. 70% ethanol 
2. Minimum Essential Medium (MEM) culture media, Gibco, Invitrogen, Grand Island, NY 
3. Dissociation media 
4. Heat inactivated horse serum Gibco, Invitrogen, Grand Island, NY (26050070) 
5. Heat-inactivated fetal bovine serum, Gibco, Invitrogen, Grand Island, NY (10082-147). 
6. Penicillin/Streptomycin, Gibco, Invitrogen, Grand Island, NY (15140-163). 
7. Trypan blue staining solution, (T8154, Sigma) 
 
Maintenance of Cultures 
1. 70% ethanol 
2. Heat inactivated horse serum Gibco, Invitrogen, Grand Island, NY (26050070) 
3. Heat-inactivated fetal bovine serum, Gibco, Invitrogen, Grand Island, NY (10082-147). 
4. Penicillin/Streptomycin, Gibco, Invitrogen, Grand Island, NY (15140-163). 
5. Minimum Essential Medium (MEM) culture media, Gibco, Invitrogen, Grand Island, NY 
6. Phosphate buffered saline (PBS) (554781, BD biosciences, San Diego, CA 92121, USA) 
 
Equipment  
Coating Cell Culture Plates 
1. Autoclave 
2. 6-well cell culture plate 
3. Laminar-flow cell culture hood with ultraviolet (UV) light 
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4. Portable power pipette filler/dispenser 
 
Mixed Glial Cell Isolation 
1. Autoclave 
2. Laminar -flow cell culture hood with ultraviolet (UV) light 
3. CO2 incubator (37°C, 95% room air/5% CO2, 95% humidity) 
4. Dissecting microscope  
5. Low speed (60 rpm) stir plate 
6. Low speed centrifuge (<1000 x g) with swinging bucket rotor and 50ml conical tube adapters 
7. Portable power pipette filler/dispenser 
8. Inverted phase-contrast microscope 
9. Hemocytometer 
10. Hand-held counter 
 
Microglial isolation 
1. Autoclave 
2. Laminar -flow cell culture hood with ultraviolet (UV) light 
3. CO2 incubator (37°C, 95% room air/5% CO2, 95% humidity) 
4. Dissecting microscope  
5. Low speed (60 rpm) stir plate 
6. Low speed centrifuge (<1000 x g) with swinging bucket rotor and 50ml conical tube adapters 
7. Portable power pipette filler/dispenser 
8. Inverted phase-contrast microscope 
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9. Hemocytometer  
10. Hand-held counter 
 
Maintenance of Cell Cultures 
1. Autoclave 
2. Laminar -flow cell culture hood with ultraviolet (UV) light 
3. CO2 incubator (37°C, 95% room air/5% CO2, 95% humidity)  
4. Portable power pipette filler/dispenser 
 
Disposable Tools for Animal Dissection and Cell Dissociation:  
Mixed Glial Cell Isolation 
1. Sterile pipettes, disposable borosilicate glass: 146 mm (5 ¾ inch) and  229 mm (9 inch) 
2. Serological pipettes, cotton-plugged disposable borosilicate glass, 10 ml short length 
3. Sterile 5 ml disposable syringes (53500-420 , VWR, Batavia, IL 60510, USA) 
4. Syringe filter with 25 cm cellulose acetate membrane, 0.2 µm pore size (4612, Pall 
corporation, Ann Arbor, MI, 48103, USA) 
5. Sterile serological pipettes, cotton-plugged disposable polystyrene, individually wrapped: 1 
ml, 5 ml, 10 ml, and 25 ml (Midwest Scientific, 280 Vance Road, St. Louis , MO, 63088, 
USA) 
6. Sterile vented cell culture flasks: 225cm2 (353138, BD falcon, Franklin Lake, NJ, 07417, 
USA)  
7. 4 x 3 inch sterile dressing sponges (82004-740, VWR, Batavia, IL, 60510, USA) 
8. 15 ml polystyrene centrifuge tubes, sterile (21008-216, VWR, Batavia, IL, 60510, USA) 
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9. 50 ml polypropylene tubes, sterile (82018-052, VWR, Batavia, IL, 60510, USA) 
 
Microglial isolation 
1. Sterile serological pipettes, cotton-plugged disposable polystyrene, individually wrapped: 1 
ml, 5 ml, 10 ml, and 25 ml (Midwest Scientific, 280 Vance Road, St. Louis , MO, 63088, 
USA) 
2. 50 ml polypropylene tubes, sterile (82018-052, VWR, Batavia, IL, 60510, USA) 
3. 6 well cell culture plate (353502, BD falcon, Franklin Lake, NJ, 07417, USA) 
 
Maintenance of Microglial Cultures 
1. Sterile serological pipettes, cotton-plugged disposable polystyrene, individually wrapped: 1 
ml, 5 ml, 10 ml, and 25 ml (Midwest Scientific, 280 Vance Road, St. Louis , MO, 63088, 
USA) 
Non-disposable Tools for Animal Dissection and Cell Dissociation:  
Surgical apparatus is non-disposable and must be autoclaved before use. Clean it thoroughly 
immediately after use.  
1. Dumont forceps (Pattern #5), 110 mm length, tip 0.1 x 0.06 mm, 2 each (25719-066, VWR, 
Batavia, IL, 60510, USA) 
2. Curves forceps, 4 inch length, full curve, 0.8 mm tip width, 2 each (82027-392, VWR, 
Batavia, IL, 60510, USA) 
3. Curves forceps, 4 inch length, full curve, 0.4 mm tip width, 2 each (82027-406, VWR, 
Batavia, IL, 60510, USA)  
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4. Micro-dissecting scissors, 4 inch length, 25 mm angled blade, 3 each (89049-674, VWR, 
Batavia, IL, 60510, USA)  
5. Mayo scissors, 7 inch length, 50 mm curved blade (95039-258, VWR, Batavia, IL, 60510, 
USA) 
6. 50 ml beaker and stir bar (length, 25 mm)  Cover top with foil prior to autoclaving 
7. Pipette sterilizing metal boxes: for 5 ¾ inch Pasteur pipettes, 9 inch Pasteur pipettes, and 10 
ml glass serological pipettes (20171-042, VWR, Batavia, IL, 60510, USA) 
8. Surgical instrument tray, autoclavable (62687-069, VWR, Batavia, IL, 60510, USA) 
 
BASIC PROTOCOL 
The algorithm is listed below:  
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Time-dated Pregnant Rat Delivery Schedule   
We schedule pathogen-free time-pregnant (prenatal day 14; PD14) Sprague-Dawley rats to arrive 
at the animal facility one week prior to their delivery date (PD21). The number of ordered 
pregnant rats is calculated based on the fact that one female Sprague-Dawley rat normally gives 
birth to 10-14 pups. The time-dated pregnant rat delivery allows us to isolate cultures on a 
consistent basis. We prepare cultures every Wednesday afternoon using 1-day-old pups, so we 
routinely order pregnant rats for Tuesday delivery to allow them to acclimate for a week prior to 
delivery. This also is cost effective, as we do not need to maintain our own breeding colony and 
incur extensive per diem charges. In the long run we find it cost effective as it also frees our staff 
and students from frequenting the animal facility for husbandry checkups, determination of plugs 
(PD1), etc.   
 
Mixed Glial Cell Preparation 
The protocol described here is composed of two continuous steps. The first step focuses on 
dissecting rat cortices and the second one entails the dissociation of glial cells including 
astrocytes, microglia and small amount of oligodendrocytes. These two steps should be 
performed consecutively.  
 
Step 1: Dissection of Neonatal Rat Cortices  
1. Gently hold and rinse the head and neck of the pup with 70% ethanol. 
2. Decapitate the head on to a sterile gauze pad using sterile curved scissors. The body is placed 
in the bio-hazard plastic bag for disposal. The surgical apparatus is placed in the 70% ethanol 
between decapitations to avoid contamination.   
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3. Use sterile fine angled dissecting scissors to cut the skin as well as skull at a slight upward 
angle from the foramen magnum to the eyes along the midline. Extra caution is needed to 
avoid damaging the brain cortices. The skull flaps can be very easily cut off to simplify the 
removal of the brain tissue 
4. With the 0.8 mm tip curved forceps sever the olfactory bulbs at the anterior part and the 
spinal cord at the posterior part of the brain. Gently move forceps with a slight back angle 
pulling up the brain. This will separate the whole brain from the skull base. During the 
procedure, the optical nerves can be easily identified; it is not necessary to preserve them.  
5. Place the brain in HBSS in 100mm Petri dish on ice and observe the separated brain under 
the dissecting microscope.  
6. Gently slip one side of the 0.4 mm tip curved forceps under the corticies on either side of the 
brain so the forceps sit astride the brain. 
7. Gently move forceps from side-to-side and with a slight back angle pull up of the cortices.  
This will separate the cortices from the rest of the brain.  
8. With the Dumont forceps, gently tease away the meninges coverings on the cortical surface 
without damaging it.  
9. Flip over the cortices to expose the underside of the tissue to make sure remove any extra 
tissues.  
10. You should be able to see the darker hippocampal crescents that need to be gently removed 
with the curved forceps. 
11. Once each cortex is dissected, place in a sterile 50 ml conical tube containing 10 ml S-MEM 
+ antibiotics on ice.  Limit the total procedure within 10 minutes to minimize the damage. We 
are able to finish the whole procedures within 5 minutes after practice.  
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12. Repeat the same procedure in the rest pups.  
13. Place the cortices in the 50 ml tube on ice until the desired number of pup brains has been 
dissected.  
 
Step 2: Dissociation of Glial Cells  
1. Carefully remove as much of the S-MEM as possible with a sterile cotton-plugged 9” Pasteur 
pipette taking care to retain all of the cortices. 
2. Add 12 ml of 37C dissociation media to the 50 ml beaker and gently pulverize the cortices 7 
–8 times using a Sigmacote® treated (see Support Protocol 1) 10 ml glass pipette. 
3. Stir for 10 minutes at low speed (1 revolution per second) in the laminar-flow hood. 
4. While this is stirring, prepare two 15 ml sterile conical tubes for each extraction.  Add 5 ml 
of growth media to each tube.  At this time, also thaw the DNase I and place it on ice.  
5. After ten minutes of gentle stirring, remove the beaker from the stir plate and place at a 45° 
angle for 2 - 3 minutes to allow the non-dissociated tissue to collect at the bottom of the 
beaker.  Resting the edge of the beaker on a lid from a culture dish works well. 
6. Carefully aspirate 10 ml of the dissociated cells with a Sigmacote® treated 10 ml glass 
pipette.  Take care not to disturb the undissociated tissue pieces. 
7. Place 5 ml into each of the two 15 ml centrifuge tubes containing the 5 ml of growth media.  
Invert the mixture 2 – 3 times to mix the cell suspension and growth media.  The serum in the 
growth media acts to inhibit dispase and prevents over digestion of the dissociated cells. 
8. Add another 10 ml of 37C dissociation media to the 50 ml beaker and add 100 l of DNase 
I.  Continue to stir for another 10 minutes.  Note the DNase I is added only after the first 
extraction and is not added again. 
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9. Place the 50 ml beaker at an angle for 2 –3 minutes, remove 10 ml of dissociated cells, and 
place 5 ml into another pair of 15 ml tubes containing 5 ml growth media as before. 
10. Add another 10 ml of 37°C dissociation media to the tissue in the 50 ml beaker and stir for 
10 minutes.  (Do not add DNase I again.)  The removal of dissociated cells and replacement 
with 10 ml dissociation media is called an extraction. 
11. Extractions are repeated until there is only fibrous tissue remaining in the 50 ml beaker.  The 
number of extractions is usually equal to the number of dissected brains. 
12. Allow each pair of 15 ml conical tubes to sit undisturbed during the continuing extractions.  
During this time, undissociated tissue will settle to the bottom of the 15 ml tube.  This 
undissociated tissue is placed back into the 50 ml beaker for further dissociation during the 
final two extractions.  
13. To remove undissociated tissue from the 15 ml tubes, insert a sterile cotton-plugged 
Sigmacote® treated 9” Pasteur pipette to the bottom of the tube and carefully aspirate the 
undissociated tissue. Place this tissue back into the 50 ml beaker for further dissociation.  
This is done only during the final two extractions because serum carried over from the 
completed extractions can inactivate the dispase. 
14. Once all of the extractions have been processed, pool the dissociated cells and media from 
the 15 ml centrifuge tubes into 50 ml conical tubes.  Centrifuge the 50 ml tubes for 10 
minutes at 500 rpm in a swinging bucket rotor to pellet the suspended cells. 
15. Carefully aspirate the media from the cell pellets. 
16.  Resuspend the cells in 20 ml growth media per 50 ml tube by gentle pipetting with a 10 ml 
Sigmacote® treated glass pipette.  
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17. Allow cells to sit for an additional 5 minutes and remove any sedimented tissue as before 
with a 9” Pasteur pipette.  Discard this undissociated tissue. 
18. Pool the suspended cells into 50 ml tubes on ice. 
19. Determine the total and viable cells by gently mixing 100 µl cells with 100 µl diluted trypan 
blue staining solution.  Allow the cells to take up the trypan blue for 5 min and determine cell 
number and viability with a hemocytometer.  
20. Dilute cell suspension to 10,000 viable cells/ml with growth media. 
21. Pipette 2,500 viable cells/cm2 into 225 cm2 culture plates and then add growth media to the 
final volume of 75 ml.  
22. Unlike culturing astrocytes, the media must not be changed until 7 days after plating to allow 
mixed glial cells to attach.  Approximately 5~ 10 % of the mixed glial cells plated will attach 
and grow on the coated plastic surface over the next 1.5~ 2.5 weeks.   
23. When changing media, insert the 5 inch Pasteur pipette and aspirate the media. Change the 
Pasteur pipette frequently and when it may have touched anything but inside of the culture 
flasks.  A pipette contaminated during media changes can easily infect the entire culture if it 
is not changed.   
24. Add 75ml fresh culture media to using a large disposable pipette.   
25. Media is changed twice per week.  If the culture media turn turbid, the cells should be 
discarded and the possibility of contamination should be suspected.   
 
Isolation of Microglia from the Mixed Glial Culture: 
1. Check the mixed glial cell culture under inverted phase-contrast microscope 
approximately 2 weeks after the initial plating, when astrocytes reach 100% confluence. 
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The microglia are growing on the top of single layer of astrocytes as small rounded cells. 
Adjusting the fine focus of the microscope assists in distinguishing the different cell 
layers.  
2. Put the cell culture flask on the flatten surface and gently bang on the side and tap the 
flasks at the speed of 45 times per minutes. Try to minimize the amount of foam 
generated when shaking the cell culture flasks.  
3. While tapping and shaking the cell culture flask, prepare the centrifuge. In our laboratory, 
we use a PRECISION Durafuge 200R centrifuge (PRECISION, 170 Marcel Drive, 
Winchester, VA, USA) and set the temperature to 4°C. Based on our experience, it takes 
about 20 minutes to cool down from room temperature to 4°C. This may vary based on 
the type of centrifuge available to you so make sure it is ready for use at the appropriate 
temperature as you are isolating the cells to prevent any delays. 
4. Check the cell culture flask under the inverted phase- contrast microscope every 3 
minutes to make sure the monolayer astrocytes are not disturbed and continue to adhere 
to the substratum of the flask.  
5. The detached microglia float in the media, while the astrocytes remain attached to the 
bottom.  
6. If attached microglia are observed, keep shaking the flasks until almost all microglia are 
floating. Using this method, after gentle shaking of the flasks for 9-12 minutes we are 
able to get almost all of the microglia without disturbing the adherent astrocytes.  
7. If astrocytes are sheared from the bottom, immediately stop shaking the flasks. If the 
harvested cells are contaminated with significant amounts of astrocytes, this may be 
caused by two reasons: 1) shaking is too rigorous; 2) astrocytes are not sufficiently 
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healthy to remain attached to the substratum of the flask. If astrocytes readily detach from 
the flask consider changing fresh culture media more frequently (three rather than two 
times per week). Please refer to the Troubleshooting section for additional details.  
8. After most microglia are detached, stop shaking and carefully aspirate the culture media 
and put it into pre-chilled 50 ml conical tube.  
9. Spin down the cells at 1000 RPM at 4°C for 5 minutes using PRECISION Durafuge 
200R (or a similar device) with a swinging bucket rotor to pellet the suspended cells.  
10. Carefully aspirate the media without disturbing the cell pellets. 
11. Resuspend the cells in 5 ml growth media per 50 ml tube by gentle pipetting with a 10 ml 
Sigmacote® treated glass pipette.  
12. Pool the suspended cells into 50 ml tubes on ice. 
13. Determine the total and viable cells by gently mixing 100 µl of cells with 100 µl of 
diluted trypan blue staining solution.  Allow the cells to take up the trypan blue for 5 
minutes and determine cell number and viability with a hemocytometer. Stained cells are 
dead; those that exclude the trypan blue are considered alive. 
14. Dilute cell suspension to 20,000 viable cells/ml with growth media. 
15. Pipette 5,000 viable cells/cm2 into each well of six-well cell culture plates and add 
growth media to a final volume of 2ml/well.  
16. The isolated primary microglia are maintained in a CO2 incubator (NAPCO series 
8000DH, Thermo Scientific, San Diego, CA 92121, USA) (37°C, 95% room air/5% CO2, 
95% humidity) for 48 hours before the experiments are initiated. Our experience dictates 
the purity of isolated microglia culture is >95% [immunostaining for the  microglial 
specific marker, OX42 (Fig 1)].  
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17. The leftover cells in the culture flasks are mainly astrocytes and they are removed by 
trypsinization. The protocol introduced here is ideal for the concomitant isolation of both 
microglia and astrocytes. The detailed protocol of isolation and culturing primary 
astrocytes has been published by our laboratory before [208]. Trypsin is most effective at 
a pH between 7.0 and 8.0 and between 24°C and 37°C at 0.05 % to 0.5 % concentration. 
The trypsinization time required for cells removal from the plates depends on their 
density, serum concentration and temperature. EDTA is often added to the trypsin to 
intensify enzyme activity by chelating calcium and magnesium. 
18. Add 10 ml of warm phosphate buffered saline (PBS) and rock the flask to wash he 
monolayer briefly. This assures the removal of the last traces of serum. Astrocytes should 
not be left in PBS for more than 10 minutes to avoid excessive cell damage.  
19. Aspirate the PBS with a Pasteur pipette.  
20. Add 2ml 1X trypsin (37°C) and rock the flask gently to cover the entire surface with 
trypsin.  
21. Leave the flask in a CO2 incubator (37°C, 95% room air/5% CO2, 95% humidity) for 5 
minutes.  
22. When the cells are loose, add 10 ml of fresh culture media with serum and resuspend the 
cells.  
23. Dilute cells to 10,000 viable cells/ml growth media.  
24. Pipet 2,500 viable cells/cm2 into each well of the six-well cell culture plates and add 
growth media to a final volume of 2ml/well. The isolated astrocytes are maintained at 
CO2 incubator (37°C, 95% room air/5% CO2, 95% humidity) for 5 minutes. The purity of 
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astrocytes in our hands reaches >95%.  We routinely test the purity by 
immunohistochemistry staining for the astrocyte specific marker, GFAP (Fig 2).  
 
Support Protocols: 
Support Protocol 1: Fire Polishing and Sigmacoat® Treatment of Pipettes for Cell Isolation 
The fire polished and Sigmacote® treated pipettes are only used for cell isolation, not routine 
changing of media. These pipettes need to be fire polished and Sigmacoat® treated. In our 
laboratory, we routinely fire a batch of 50 pipettes for each planned microglial cell isolation.   
1. Fire polished tips of 9 inch Pasteur pipettes by placing the small end in an open flame 
from a Bunsen burner for a few seconds.  This will slightly melt the borosilicate glass and 
will produce a smooth tip to the pipette which helps prevent damage to the cells.  Take 
care not to make the diameter of the opening too small as this can increase the shear 
forces during triturating and may lead to increased cell damage. 
2. Plug the large end of the Pasteur pipettes with cotton. The amount of cotton obtained 
from a single cotton tipped swab is sufficient for each pipette.   
3. Treat each pipette with Sigmacote® by drawing the viscous solution up into the Pasteur 
pipette without touching the cotton plug.  Allow the Sigmacote® to drain back into the 
bottle and place the Pasteur pipette in a beaker with paper towels lining the bottom to 
drain and dry completely. 
4. Once the Pasteur pipettes are dried, place them in a metal container and autoclave.10 ml 
glass serological pipettes should also be Sigmacote® treated and autoclaved.  Fire 
polishing of these pipettes is unnecessary. 
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Supporting Protocol 2: Coating Cell Culture Plate with Poly-L-Lysine.  
We routinely culture isolated microglia in the poly-L-lysine coated six-well cell culture plate. 
Prepare borate buffer according the following recipe:  
1. prepare coating buffer by dissolving 2mg poly-L-lysine into 50ml borate buffer; 
2. add 1 ml coating buffer into each well;  
3. let it stand for 1 hour in the tissue culture hood with UV light on; 
4. aspirate the coating buffer and wash the well with distilled water for three times  
5. air dry the cell culture plate in the tissue culture hood for at least one hour with UV light 
on; 
6. Add 1 ml MEM culture media without antibiotics or serum into each well and store the 
plate in 4°C. The coated plate could be stored safely for one week.  
 
REAGENTS AND SOLUTIONS 
Reagents: 
1. Culture Media:  
 Minimal Essential Medium, with Earle’s salts and L-Glutamate (MEM), Gibco, Invitrogen, 
 Grand Island, NY (11095) 
  Minimal Essential Media, with Earle’s salts, modified for suspension cultures (S-MEM), 
 Gibco, Invitrogen, Grand Island, NY (11385). S-MEM has been modified to contain no Ca+2 
 which can produce cell clumping due to interactions of extracellular matrix proteins.   
2. Antibiotics: 
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  Penicillin G (10,000U/ml)-Streptomycin Sulfate (10,000 g/ml), Gibco, Invitrogen, Grand 
 Island, NY (15140-163). Avoid repeated freeze- thaw cycles of penicillin/streptomycin by 
 storing 10ml aliquots at -20°C. 10 ml penicillin/streptomycin is enough for 1 L of media. 
Fungizone® (Amphotericin B, 250 g/ml), Gibco, Invitrogen, Grand Island, NY (15290-018). 
Fungizon is optional, to prevent fungal or yeast contamination.  
3. Serum: 
Heat-inactivated horse serum, Gibco, Invitrogen, Grand Island, NY (26050070) 
Heat-inactivated fetal bovine serum, Gibco, Invitrogen, Grand Island, NY (10082-147). 
Avoid repeated freeze-thaw cycles of serum.  Put the frozen serum in the water bath no 
warmer than 40°C until serum is thawed. The thawed serum could be safely stored at 4°C 
for approximately one week.  
4. Protease (dispase), Gibco, Invitrogen, Grand Island, NY (17105-041).  
5. Deoxyribonuclease I (DNase I) from Bovine Pancreas Type IV, Sigma Chemical Company, St. Louis, 
MO (D-5025). DNase I is added immediately after the first extraction to prevent the genomic DNA 
released by damaged cells from making the dissociating media too viscous during the ongoing 
digestion. Avoid vortex when handling DNase I as it is vulnerable to inactivation by physical 
damage.   
6. Poly-L-lysine Hydrobromide (P-1274), Sigma, 3050 Spruce St. St. Louis, MO 63103.   
7. Trypan blue 0.4%, liquid, sterile-filtered, cell culture tested (T8154). Trypan blue is  used 
determine cell viability. Dead or damaged cells cannot exclude trypan blue,  so they appear 
blue under the microscope.   
8. Sigmacote® (SL-2),  Sigma, 3050 Spruce St. St. Louis, MO 63103. Sigmacote is a special 
silicone solution in heptane that readily forms a covalent, microscopically thin film on 
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glass, retards clotting of blood or plasma. It bonds with the uneven surface of the glass 
pipettes and provides a smooth hydrophobic barrier. The adherence of cells to the glass 
surface is greatly reduced, and thus minimizing physical damage to the cells. 
9. Distilled Water, cell culture tested, Gibco, Invitrogen, Grand Island, NY (15230-147). All 
solutions used in this protocol should be prepared in cell culture tested double distilled 
water. 
10. Boric Acid, J.T.Baker, 222 Red School Lane, Phillipsburg, NJ (10043-35-3).  
11. Borax (71997), Sigma, 3050 Spruce St. St. Louis, MO 63103. 
 
CRITICAL PARAMETERS 
Dissecting neonatal rat cortex:  The meninges should be completely removed; otherwise the 
mixed glial culture may become contaminated with large amount of fibroblasts as the 
proliferation of fibroblast is much faster than glial cells. An efficient surgical technique is critical 
for obtaining high quality tissue dissection. Avoid spending more than 10 minutes on dissecting 
brains to minimize the ischemic damage to the brain tissue.  
 
Dissociation of cells:  According to our experience, there is significant variability in the quality 
of dispase used in this protocol. In general, if a rapid and continuing decrease in cell number or 
viability is observed, dispase should be changed to newly purchased lots. The use of Sigmacote® 
treated glass pipettes greatly enhances the quality of dissociated cells because it significantly 
reduces the trauma to cells during the isolation process. We have observed that harsh maneuver 
results in a large reduction in the cell viability.   
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Isolation of Primary Microglia: In general, isolation of microglia by shaking flasks should be 
gentle to avoid forceful trituration that introduces air bubbles into the suspensions. It is important 
to change culture media twice a week (or more, should astrocytes detach from the substratum 
during the tapping process) to keep cells healthy; otherwise, astrocytes could be sheared during 
the isolation procedure very easily. Keep checking the cells under the inverted microscope every 
3 minutes in order to minimize the amount of astrocyte contamination.  
 
Cell Culture Purity:  The primary microglial culture obtained by our protocol is routinely >95% 
positive for OX 42 [209] by immunohistochemistry (See Figure 1). Unlike non-glial cells, 
microglia should be cultured in Poly-L-lysine or collagen I coated plates. It has been suggested 
that using rat pups 24 to 48 hours old may decrease the number of contaminated neurons [210]. 
The small spikes in primary microglia could be very easily observed under microscope with DIC 
settings (Fig 1).  
 
Coating Material: Primary microglia should not be cultured on uncoated plastic surface or glass 
surface. In our laboratory, we used both poly-L-Lysine and collagen I coated cell culture plates. 
One of the unique features of primary microglia is that the phenotype could be different based on 
different coating materials. Cells are wide spread on Poly-L-lysine coated surface, but microglia 
grow in clusters on the collagen I coated surface. Therefore, choosing which coating material to 
use should be carefully considered within the context of the experimental design.  
 
Culture Time: Unlike malignant cells, primary microglia stop proliferating and growing once 
confluence is reached. Consideration should also be directed at the possibility that different 
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confluence level may cause significant variations in experiment results [144]. Therefore, it is 
strongly recommended that the effects of confluence be determined by treating cultured 
microglia at different confluence levels. Furthermore, experiments should be conducted in 
triplicates (at a minimum) derived from several independently isolated cultures.  Experiments 
must use cultured cells at the same confluence in order to minimize this confounding factor. At 
our hands cultured microglia reach 50% confluence two weeks after isolation from the mixed 
glial culture preparations.  
 
Contamination:  If the culture media turn turbid, contamination should be suspected and all 
infected culture flasks must be disposed immediately. Rapid and accurate identification of the 
offending microbe is very helpful, but rarely could be done in the laboratory settings. The most 
common pathogenic microbial include Staphylococcus aureus, Staphylococcus epidermidis or 
Streptococci, though some rare microbe could be possible such as microplasma, fungi or viruses. 
The contamination caused by microplasma or viruses could be very difficult to identify because 
the culture media do not turn turbid. The only sign of microplasma or virus infection is that a 
large number of cells fail to attach to the substratum. The microbial contamination is most likely 
to occur during the initial cell isolation, thus sterilization of surgical tools and cleaning of all 
surface with 70% ethanol are critical to minimize microbial contamination.   
 
 
TROUBLESHOOTING 
Clumping of cells during the extraction: Cell clumping causes significant cell damage 
during the cell isolation. Ca2+ in the regular MEM could interact with the extracellular 
 130 
 
proteins, which lead to cell clumping. The cell clumping should be differentiated from tissue 
sedimentation by its size. Cell clumping is much smaller than tissue sedimentation and 
checking the sedimentation under microscope could be very easily tell them apart. It is 
recommended to use S-MEM without Ca2+ during cell isolation to prevent cell clumping.  
 
Media becomes very viscous during extraction: It is caused by genomic DNA release from 
damaged cells and adding DNase I immediately after the first extraction could very well 
solve it. The DNase I solution should not be vortexed as it is vulnerable to inactivation by 
physical damage.  
 
Large area of monolayer of astrocytes sheared off during isolation of primary microglia: It 
is most likely caused by too vigorous shaking of the cell culture flask, especially if the 
researcher has limited experience in the isolation procedure. We recommend starting with 
less vigorous physical maneuver and checking the cells under the inverted microscope every 
three minutes, adjusting the level of vigorousness based on the isolation outcome. Changing 
the old with fresh culture media could also help to mitigate this problem.  
 
COMMENTARY 
Background Information 
Microglia play a critical role as resident immunocompetent and phagocytic cells, serving as 
scavenger cells in the event of infection, inflammation, trauma, ischemia and neurodegeneration. 
Thanks to the advancement of cell culture techniques, research on the biochemical, 
physiological, pharmacological and molecular aspects of microglial function are possible. The 
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culture technique provides an ideal model to study the microglial function under controlled and 
reproducible conditions.  
 
Given the wide array of microglial functions, the possible uses for primary cultures are endless. 
A brief list includes, studies on the role of microglia in immunity [211], protective effects of 
microglia on co-cultured neurons [212], modulators of microglial secretion of growth factors 
[213] and cytokines [155, 214], and the role of free-radicals production in neuropathology [156], 
just to name a few.  The receptors of microglia contribute to the modulation of CNS 
microenvironment and functions. For example, the main functional ionotropic glutamate 
receptors (iGluRs) in cultured rat microglia are mostly AMPA (D,L-α-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid) receptor, which inhibits TNF-α release and helps to modulate 
glutamate level in the CNS. Furthermore, perturbations in the homeostasis of this transmitter 
have been reported in neurodegenerative diseases [215]. Microglia also express GABAB (γ-
aminobutyric acid ) receptor that inhibits IL-6 release from the activated microglia [215].  In 
addition, these cells express a variety of purinergic receptors (P2Y12, P2Y6, P2Y7 AND P2Y4), 
which regulate the migration and cytokine release. Furthermore, microglia exhibit anti-
inflammatory effects by expressing adrenergic, dopaminergic and cholinergic receptors [215].  
Studies on the function of the above parameters are all amenable to in vitro cultured microglia, 
and indeed, over the last several decades a plethora of experimental approaches have enriched 
our understanding on the role of these cells in health and disease. 
 
Though microglial cells can be readily isolated and have clearly received experimental attention, 
many studies have utilized microglial cell lines instead of primary cells to test their functions in 
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various physiological and pathological conditions[144]. Although immortalized cell lines, such 
as murine N9 are less expensive and less time consuming to prepare and maintain, and there is 
less culture- to- culture variation in these cell lines, it needs to be considered that cell lines are 
derived from either tumors or are genetically modified to proliferate unlimitedly. Thus results 
generated from cell lines may lead to erroneous interpretations. Primary microglia have 
advantages over the immortalized cells more closely representing their in situ counterparts. 
However, analogous to any type of cultured cells, one must be cautious when relating processes 
seen in cultured microglia and extrapolating to in vivo conditions as primary cells are grown in 
isolation and lack the normal CNS microenvironment. The interaction between multiple cell 
types in the brain such as neurons, astrocytes, oligodendrocytes and microglia is exceedingly 
difficult to be modeled in vitro. Regardless what isolation protocol is used (for additional 
methods see below), it is important to keep in mind that one must be cautious in correlating the 
in vitro data generated from cultured primary microglia with their physiological and pathological 
profile in living animals. Issues related to the advantages and disadvantages offered by cell 
cultures have been previously addressed and apply to any cell type.  
 
There are additional published methods to isolate primary microglia. Frank and Maier [216] 
reported a density gradient centrifugation method of homogenized hippocampal tissue in a 
0/50/70% Percoll (Amersham Biosciences, Uppsala, Sweden) gradient that yields enriched rat 
primary microglia. The primary microglial cells are located at the 50/70% Percoll interface. The 
disadvantages of this protocol include long centrifugation (45 minutes) at 20°C as well as the 
homogenization of brain tissue before the spin down. The homogenization procedure may cause 
excessive cell damage and the subsequent long spin down time may further decrease the 
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microglial yield, thus selecting for a specific (potentially hardy) microglial phenotype. Hassan 
and Douglas introduced another protocol to isolate human [217], mouse [218] and rabbit [219] 
primary microglia using orbital shaker. Briefly, flasks with the mixed glial culture are shaken in 
an orbital shaker for 16 h at 150 rpm at 37°C. The supernatant media are then centrifuged for 10 
minutes at 1,200 r.p.m at 4°C. This method is short and saves labor, and also yields large 
amounts of primary microglia. Nevertheless, the sequalae of 16 h shaking on the functional and 
morphological properties of microglia needs to be considered and evaluated.  
 
We do not recommend passaging of the mixed glial cell cultures. One may consider trypsinizing 
mixed glial cultures, splitting cells into more culture flasks and allowing them to grow until 
confluence (passage of cells). Although this will result in a greater glial cell yields, it should be 
considered that cell passaging may change their biochemical and immunological phenotypes 
(Cole and de Vellis, 1992). Therefore, we do not recommend this approach and advocate fresh 
isolations of microglia to obtain a constant supply of primary cells. .  
 
Regardless what isolation protocol used, it is important to keep in mind that one must be cautious 
to correlate the in vitro data generated from cultured primary microglia with the physiological 
and pathological profile in the living animals.  
 
ANTICIPATED RESULTS 
The protocol described above results in the isolation of microglial cultures that exceed 95% 
purity [by immunohistochemical staining for the specific marker, OX42 (Fig 23)]. The primary 
microglia seeded and grown on Poly-L-lysine coated plastic surface do not grow in clusters, so 
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that fine structures on the cell membrane could be observed in detail (Fig 25A). Conversely, 
cultured primary microglia seeded on Collagen I grow in clusters (Fig 25B). Cell yields reach 
1,000,000 microglial cells per brain with viability approximating 90%. Most isolated primary 
microglia (>90%) adhere to the coated cell culture plates 24 hours after the isolation. The fresh 
culture media can be changed 72 hours after initial isolation if necessary. Our experience dictates 
that 6,000,000- 8,000,000 cultured primary microglia provide ample RNA or protein for most 
real-time PCR or western blot procedure.  
 
THE CONSIDERATIONS 
The total time spent on the preparation of mixed glial culture is approximately 6 hours depending 
on the number of extractions performed and the number of rat pups used. The mixed glial cell 
culture is maintained in 225 cm2 cell culture flasks on average for 2 weeks (dependent upon the 
endpoint of your experiment; obviously if you desire to study developmental changes, you may 
study the cells at earlier time points, keeping in mind that replicates should be at the same 
developmental stage and confluence). The twice weekly changing of media takes about 2 hours 
based on the number of flasks. It is recommended to feed the cells more frequently if the 
astrocytes adhere to the bottom very loosely. The isolation of primary microglia usually takes 
about 3 hours.  
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Fig 23  
 
 
 
 
The purity of isolated primary microglia exceeds 95% as verified by immunohistochemistry 
staining for the microglia specific marker, OX 42. The nuclei are counterstained with 4',6- 
diamidino- 2- phenylindole (DAPI).  
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Fig 24  
 
 
 
 
The purity of leftover astrocytes exceeds 95% as verified by immunohistochemistry staining for 
the astrocyte specific marker, GFAP. The nuclei are counterstained with DAPI.  
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Fig 25  
 
 
DIC images of cultures primary microglial cells. Fig. 25A shows the isolated primary microglial 
cells cultured on Poly-L-lysine coated plastic surface and Fig. 25B shows the cells cultured on 
Collagen I coated surface. Different coating materials produce different morphological attributes 
in these cells. In general, cells are widely spread when grown on poly-L-lysine (Fig. 25A) coated 
plastic surface with small spikes easily observed. Collagen I causes the microglia to grow in 
clusters (Fig. 25B).  
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B. Book chapter: Developmental Toxicity and Molecular Changes Induced by MeHg 
Exposure in Laboratory animals and humans. 
 
This chapter has been published in  
Chapter 34, Section 7, 
Reproductive and Developmental Toxicology 
 
Introduction  
Human exposure to mercury (Hg) is mainly in the form of methylmercury (MeHg) 
predominantly from the consumption of fish [12-14]. Nearly all fish contain detectable amounts 
of MeHg (Clarkson et al, 1988). MeHg enrichment in the aquatic food chain is not uniform and 
is dependent upon water Hg content, bottom sediments, water pH and redox potential, the 
species, age and size of the particular fish. Furthermore, environmental conditions, such as 
anoxia, favor the growth of microorganisms and increase the methylation rate of Hg [15] and, by 
inference, its accumulation in fish. The mechanisms of Hg methylation in oceans and waterways 
are not fully understood.  
 
 The aims of this chapter are to outline the kinetics of organic mercury (MeHg) in humans and 
the toxic effects of MeHg on the developing fetal central nervous system (CNS) as well as on 
other organ systems. Herein, we also briefly review the differences in MeHg-induced brain 
damage between the fetus and the adult. The focus of the review is to highlight several of the 
proposed mechanisms of MeHg toxicity in the developing organism and discuss directions for 
future studies to address current gaps in the literature, enhance and expand our knowledge of      
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the underlying mechanisms of MeHg toxicity and its effects upon the environment, animals and 
humans. 
 
Historical Background  
Catastrophic epidemics due to environmental MeHg contamination in Japan [5, 6] and Sweden 
[16] have been previously reported. Exposure was also documented in Iraq, where locals 
consumed bread prepared from seeds treated with a fungicide containing MeHg [25], causing a 
large outbreak of human poisoning. Similar incidents have occurred in Pakistan, Guatemala and 
Ghana [220]. School children living in polluted areas have been found to exhibit diskinesia and 
intellectual disturbances [17]. The initial symptoms of classic congenital Minamata disease due 
to MeHg exposure were mental retardation, primitive reflexes, coordination disturbance, 
dysarthria, limb deformation, growth disorder, chorea-athetose and hypersalivation [18]. These 
symptoms occurred at Hg exposure levels exceeding the U.S. EPA RfD of 0.1 µg/kg body 
weight/day (an exposure without recognized adverse effects). As mentioned earlier [see also 
2000 National Health and Nutrition Examination Survey (1999–2000 NHANES)], given that 8% 
of U.S. women of child-bearing age have blood Hg concentrations exceeding 5.8 µg/L (level 
equivalent to the current RfD), the total impact of exposure to Hg upon human populations is of 
considerable significance and may have tremendous societal consequences, affecting more than 
300,000 newborns annually in the U.S. alone. It is reasonable to suggest, considering the 
magnitude of potential susceptible populations as well as the long latency period for the 
development of Hg-induced symptoms, that the true number of those affected is even greater 
than this conservative estimate.   
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Toxicokinetics in humans        
The kinetics of MeHg in the human body is summarized in figure 1. MeHg derived from food or 
occupational exposure is efficiently absorbed (90%) and has a long retention time (half-life of 
~70 days). After ingestion, the distribution to the blood compartment is complete within 30 
hours, and the blood level accounts for about 7% of the ingested dose [19]. Circulating MeHg 
accumulates predominantly in red cells where it binds to cysteinyl residues (-SH) on the 
hemoglobin beta-chain [20], and is then slowly distributed reaching an equilibrium with other 
tissues at ~4 days [19].  
 
In the brain, MeHg undergoes slow demethylation and is converted to inorganic mercury (IHg) 
[102]. About 10% mercury is retained in the brain Following a long-term exposure to MeHg 
accumulated inorganic mercury is deposited in the cortex of the calcarine sulcus of the female 
Macaca fascicularis [102], similar to prolonged subclinical exposure in humans. Mercury is not 
universally distributed and is deposited in certain central nervous system (CNS) cell types. 
Tissue staining following six months of exposure to MeHg reveals the largest IHg deposits in 
astrocytes and microglia. The total mercury accumulation in neurons are significantly lower than 
those present in the glial cells and increase with length of exposure; virtually all neurons are 
labeled following 18 months of exposure. In contrast, endothelial cells and pericytes do not 
contain notable mercury deposits, and deposits in oligodendrocytes are rarely observed. These 
data are consistent with the hypothesis that the neurotoxicity of MeHg is mediated, at least in 
part, by glial cells and that glial-neuron interactions play important roles in the process. Notably, 
staining of mercury deposits in IHg-exposed animals is lower compared to MeHg-exposed 
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animals, supporting the observation that it is the organic form of mercury that more readily 
crosses the blood-brain barrier (BBB) [102].  
 
MeHg is incorporated into the hair during its formation. The MeHg concentration in blood and 
hair reflects the body burden, with a blood/hair concentration in humans approximating 1/250 
under steady-state conditions (Skerfving, 1974). The net mercury excretion rate in humans is 
approximately 1% of the body content at non-symptomatic body burden level [22]. Most of the 
MeHg is eliminated through the liver into the bile and through the kidney into the urine. But 
most MeHg undergoes enterohepatic circulation by reabsorbtion from the bile in the gut. Slower 
urine excretion of MeHg in female versus male rats has been reported to result in higher toxicity 
[23]. Diet can affect MeHg excretion rate, since certain dietary components can interfere with 
MeHg reabsorption in the lower part of the intestines, thus breaking up the enterohepatic 
circulation [24].  
 
Approximately 5% of the total MeHg in the maternal blood is found in breast milk [25], but the 
risk of MeHg exposure to infants through breast feeding declines rapidly during lactation, which 
is due to the rapid decrease in mercury transferred through breast milk postpartum and the fast 
growth of infants after birth [26]. MeHg crosses the placenta and accumulates in the fetus at 
concentrations higher than in the mother. For example, neonatal cord blood MeHg is more than 
twice as high as the level in maternal blood at delivery, but infant blood MeHg levels decrease 
significantly during the first 13 weeks of the infant’s life, and, at three months, maternal MeHg 
concentrations are higher than those of the infant, opposite to the situation at parturition [26]. 
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The rapid decline in infant MeHg concentrations postpartum can be explained by lower mercury 
transfer through breast milk and rapid infant growth after birth [26].   
 
Hg is covalently bound to the carbon moiety in MeHg (CH3-Hg+). The carbon-Hg bond is 
chemically stable because of the low affinity of Hg for oxygen. MeHg does not exist as a free, 
unbound cation in biological systems (except an infinitesimal amount as governed by the law of 
mass action) [29], and the organic form is highly soluble in organic solvents and lipids. MeHg 
has a remarkably high affinity for the anionic form of –SH groups (log K, where k is the affinity 
constant and is on the order of 15–23) [29]. Despite the high thermodynamic stability of the 
MeHg-SH bond, very rapid exchange of MeHg between –SH groups is known to occur [31]. In 
cells, MeHg can form a complex with the –SH-containing amino acid cysteine [30]. The MeHg-
S-Cys complex closely mimics the structure of the neutral amino acid, methionine, and is 
therefore a substrate of the L type large neutral amino acid transporter system (LAT1) [32]. This 
mimicry is responsible for MeHg uptake into cells. MeHg crosses the placenta via a similar 
neutral amino acid carrier, accumulating in fetal blood in a time- and dose-dependent manner 
[33].  
 
Over-expression of LAT1 in CHO-k1 cells has been shown to be associated with enhanced 
uptake of [14C]-MeHg when the cells are treated with L-cysteine, but not with the D-cysteine 
conjugate. In the presence of excess L-methionine, a substrate for LAT1, L-cysteine-conjugated 
[14C]-MeHg uptake was significantly attenuated. Knock-down of LAT1 decreases the uptake 
of L-cysteine-conjugated MeHg and attenuates the effects of MeHg on lactate dehydrogenase 
(LDH) leakage and CHO-k1 cell viability [32]. Notably, different neutral amino acids have 
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different suppression effects. For example, the suppression by methionine is not as remarkable as 
that produced by phenylalanine. This phenomenon could be due to the transient rapid cysteine 
surge after methionine administration, but not after phenylalanine administration. This newly 
synthesized cysteine in maternal blood accelerates the mercury uptake across the placenta.  
 
Mechanisms of MeHg Neurotoxicity 
As mentioned previously, MeHg has been found to bind to protein –SH groups of amino acids, 
such as cysteine, which is also present in glutathione (GSH) [221]. This affinity for the sulfur 
and sulfhydryl groups (–SH) is a major factor underlying the biochemical and toxic properties of 
MeHg and its interference with optimal cell function. A large body of research aimed at 
deciphering the cellular and molecular mechanisms of MeHg-induced neurotoxicity points to 
several critical features, namely: 1) inhibition of macromolecule synthesis (DNA, RNA and 
protein); 2) microtubule disruption; 3) increase in intracellular Ca2+ with disturbance of 
neurotransmitter function; and 4) oxidative stress. Nonetheless, MeHg’s primary site of action 
and the genetic bases of its neurotoxicity have yet to be identified. A brief review outlining the 
most critical features of the mechanisms involved in MeHg-induced neurotoxicity follows. 
 
MeHg reacts with DNA and RNA, resulting in changes in the secondary structure of these 
molecules [222]. Since the 1990s, epidemiological studies have suggested increased genotoxicity 
in human populations through dietary and occupational exposure [223]. MeHg inhibits DNA 
repair mechanisms, thereby leading to genotoxicity. For example, MeHg directly binds to the 
“zinc finger” core of DNA repair enzymes, affecting their activity. The “zinc finger” proteins 
contain an atom of zinc and four cysteines and/or histidines. Thus, the high affinity of mercury to 
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sulfhydryl groups on cysteines may deform the structural integrity and activity of these enzymes 
[79]. MeHg could also give rise to disturbances in protein synthesis [82, 93, 224, 225]. On the 
other hand increased protein synthesis due to reactive astrogliosis, has been reported after in vivo 
exposure to MeHg [226].  
 
The inhibition of the polymerization of tubulin by MeHg is among the major mechanisms of 
developmental MeHg toxicity [80]. Microtubular fragmentation has been reported in cultured 
primary rat cerebellar granular neurons at a MeHg concentration of 0.5–1 µM [81]. Additionally, 
it has been reported that 4 µM mercury salt, independently of the anion, is capable of inhibiting 
the polymerization of isolated tubulin in a dose-dependent manner. Further, 0.1 µM mercury salt 
is sufficient to decrease kinesin-driven motility and to produce a significant increase of 
micronuclei in V9 hamster lung fibroblasts [227]. Since microtubules participate in cell division, 
their fragmentation by MeHg results in antimitotic effects, as well as the inhibition of neuronal 
migration and the degeneration of neuritis [82], all of which are inherent to developmental MeHg 
exposure outcomes.  
 
MeHg depolarizes the presynaptic membrane, increasing Na2+ and decreasing K+ ion 
concentration. This, in turn, causes disruption of Ca2+ homeostasis leading to increased 
intracellular Ca2+ concentration [85, 86]. Blockers of voltage-dependent Ca2+ channels prevent 
the appearance of neurological signs [228]. Increased Ca2+ concentrations disrupt 
neurotransmitter signaling. Increased release of dopamine, glutamate, -amino butyric acid 
(GABA), glycine, choline [87] and acetylcholine [88] have been associated with MeHg 
exposure. Inhibition of the uptake of excitatory amino acids, such as glutamate and aspartate, has 
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also been implicated as a major mechanism of MeHg-induced neurotoxicity [89, 90]. 
Antagonists of the N-methyl-D-aspartic acid receptor have been reported to inhibit the toxic 
effects of MeHg [229].  
 
MeHg also alters the cellular energy metabolism. Chen [230] reported that highly enriched Hg 
concentrations were found in mitochondrial fractions from Hg- exposed porcine cells. Yin [107] 
reported that MeHg causes a concentration-dependent reduction in the inner mitochondrial 
membrane potential (ΔΨm) of primary cultured astrocytes. MeHg stimulates the ubiquinol: 
cytochrome C reductase complex (complex III) on the mitochondrial membrane [91], while 
inhibiting glutathione peroxidase (GPx) [92], which leads to lipid peroxidation. Fox [231] and 
Verity [93] further reported that MeHg inhibited state 3, but increases state 4 respiration, 
inhibiting tri-carboxylic-acid (TCA) cycle activity and decreasing ATP utilization. In brain 
tissues, MeHg affects respiratory control in synaptosomes both in vitro and in vivo [93, 231]. 
Effects on mitochondrial respiration in the brain have also been reported [93, 94], causing the 
inhibition of glycolysis and tri-carboxylic-acid cycle activity and a decrease in adenosine 
triphosphate utilization. Since the CNS is strictly dependent upon glucose for its energy 
production, high oxygen utilization and excitability renders it especially susceptible to toxins.  
 
Disruption of redox cellular homeostasis by excess reactive oxygen species (ROS) formation 
leading to cumulative oxidative stress represents an important feature of MeHg neurotoxicity. 
MeHg is known to induce oxidative stress [232] both in vitro and in vivo [95-97, 150, 233]. The 
production of ROS by MeHg exacerbates toxicity by facilitating cell death via apoptotic 
pathways. Inhibition of glutathione peroxidase (GPx) by MeHg further potentiates lipid 
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peroxidation. Conversely, several studies have demonstrated partial amelioration of MeHg 
toxicity in the presence of antioxidants [150, 158, 234, 235]. A major source of MeHg-increased 
ROS generation is the mitochondrial electron transport chain. The damaged mitochondrion 
increases oxidative stress, leading to a decrease in defense mechanisms. It has also been reported 
that blockage of the mitochondrial transition pore by cyclosporin A in brain synaptosomes 
decreases MeHg-induced ROS production [236]. MeHg binds to GSH, which is one of the 
principal endogenous antioxidants, and this binding is responsible for the excretion of MeHg. 
Thus, decreased GSH levels parallel the increased oxidative stress caused by MeHg [237-239]. 
Upregulation of GSH is neuroprotective against MeHg-induced neurotoxicity [240].  
 
Toxicity 
MeHg Toxicity in Developing Brains  
The brain is the primary target site for MeHg [71], and MeHg effects on the developing CNS are 
more severe than those in the mature CNS [72, 73]. There is usually a latent period of weeks to 
months between exposure and the onset of symptoms [220]. In less severe cases, psychomotor 
retardation and increased incidence of seizures have been reported [241]. In general, MeHg 
poisoning results in focal damage in adults and widespread and diffuse damage in the fetal and 
neonatal brain [74], likely reflecting the dynamic nature of the developing CNS (cell division, 
migration, differentiation, synaptogenesis). For example, the brain areas most vulnerable to 
MeHg after adult exposure include the primary sensory and motor cortices, pre- and post-central 
gyri, the temporal transverse gyrus and the cerebellum (but not Purkinje cells) [75]. In contrast, 
upon congenital exposure to MeHg, damage is more widespread, resulting in cortical atrophy, 
thinning of the corpus collosum and white matter shrinkage. Hematoxylin and eosin stain has 
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established diffuse spongiosus in the deeper layers as well as gliosis with loss of neurons in the 
upper layers [75, 76].  
 
Because the vulnerability to MeHg poisoning is age-related, with susceptibility decreasing with 
increasing age, the symptoms of mercury poisoning and mercury deposits are quite different 
depending on the age at the time of exposure [75]. Davis and colleagues followed an entire 
family chronically exposed to MeHg. An infant exposed to MeHg in utero was born mute, blind, 
and with severe mental retardation, quadriparesis, choreoathetosis and seizures. An eight-year-
old child in the same family had very similar symptoms. Both died 21 years post MeHg 
exposure. In contrast, a twenty-year-old child in the same family had a loss of peripheral vision, 
poor hand coordination and mild cognitive deficits. The parents were reported to be completely 
asymptomatic [76]. These results are consistent with previous observations reported by Berlin 
[242].  
 
It is likely that unique features of the fetal blood-brain barrier (BBB) contribute to the 
vulnerability of the fetal brain to MeHg toxicity. The fetal BBB is not fully developed until the 
middle of the first year of life, resulting in constant exposure to MeHg throughout gestation 
[243] and during early postnatal life.  It is also likely that, given the immaturity of the CNS, 
MeHg is not as efficiently excreted from the CNS, as transporters associated with this process 
are less likely to be fully developed. Furthermore, the increased burden of MeHg in general 
likely reflects the absence of an efficient mechanism(s) for excretion of MeHg via the bile. 
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MeHg causes mitotic arrest in developing neurons after prenatal exposure, and the effects of 
MeHg on neuron proliferation depend on which type neurons were forming at the time of 
exposure [243]. It is well known that the generation of neurons continues throughout gestation 
and well into the first year of life. Typically, a set of neurons destined to be similar in function 
and morphology is generated in a short period, sometimes within a few days of gestation. In 
general, large motor neurons are produced first, followed by sensory neurons. Nuclear groups in 
the brain stem and diencephalon are formed early, but the complex layered structures like the 
cerebral cortex, cerebellum and hippocampus add more neurons over a long period of time [243]. 
Therefore, in infants, diffuse neuronal degeneration is detected consistently in these early-formed 
brain structures.  
 
Further, MeHg causes incomplete or abnormal migration of neurons to the cerebellar and 
cerebral cortices as well as deranged cortical organization of the cerebrum with regard to 
heterotopic neurons. Moreover, the laminar cortical pattern of the cerebrum is disturbed, 
consisting of irregular groupings and deranged alignment of cortical layers. Although the 
molecular targets of MeHg giving rise to these outcomes are not fully understood, studies on 
MeHg’s effects in the Drosophila model suggest an altered Notch receptor pathway [244]. The 
Notch receptor pathway is a highly conserved cell-cell signaling mechanism that controls cell 
fate decision, proliferation, migration and neurite outgrowth during neural development [244].  
 
Notch receptor activation requires proteolysis by a cell surface disintegrin and metalloproteinase 
(ADAM), which is required for normal neural development. MeHg exposure promotes activation 
of ADAM resulting in a concentration- and time- dependent increase in Notch receptor activity 
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[244]. Notably, inorganic mercury is significantly less potent for inducing Notch activity as 
compared to MeHg, suggesting a mechanism specific to the organic form of mercury [244].  
 
MeHg also inhibits several fetal brain enzymes. Watanabe and colleagues reported that prenatal 
MeHg exposure significantly inhibits selenoenzymes, such as glutathione peroxidase (GPx), in 
fetal mouse brains injected with 3mgHg/kg of MeHg on gestational day 12~14 [245]. As a result, 
glutathione (GSH) is decreased and thiobarbituric acid- reactive substances (TBARS) are 
increased. Furthermore, lipid peroxidation is increased in fetal brains [246].  
 
In addition to its effects on brain structure and brain enzymes, MeHg exposure also affects 
synaptic transmission. The acute effects of mercury on the amphibian neuromuscular junction 
have been studied using the isolated sciatic nerve/sartorius muscle preparation. Results have 
indicated that mercury primarily affects presynaptic neurotransmitter release, but not 
postsynaptic processes, which include the activation of receptor-associated ionic channels and 
degradation of chemical transmitters [247, 248]. Mercury also disrupts the intracellular buffering 
of calcium, which further inhibits the calcium-dependent neurotransmitter release [247, 248]. 
Mercury first causes an increase in evoked acetylcholine release followed by a sudden and 
complete blockade [247, 248].  
 
In all age groups, myelination is greatly inhibited by MeHg. Biopsy of the sural nerve was 
performed on three patients who died of severe Minamata disease, and the results revealed 
numerous unmyelinated and poorly myelinated nerve fibers [249]. The myelinated fibers were 
scattered irregularly in small numbers or in groups of peculiar features in the intraneural bundle. 
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In addition, abnormally thin or poorly formed myelin sheaths were observed. Regenerated axons 
were extremely small in size, and sometimes the small axons were lost entirely, leaving only the 
thin myelin sheaths [249]. MeHg was also reported to inhibit UDP galactose:ceramide 
galactosyltransferase (CGalT) and  2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNP), enzymes 
involved in myelin formation [250]. Notably, MeHg has greater inhibitory effects on myelin 
formation than diethylmercury, which suggests that different forms of organic mercury produce 
different effects [251].  
 
MeHg Toxicity on Other Organ Systems 
The developing immune system is especially sensitive to the elemental forms of mercury. 
Occupational studies and animal studies have demonstrated that MeHg affects immune-cell 
ratios and cellular responses [252]. MeHg reduces natural killer (NK) cell activity [253] and 
alters the mitogen response [254] as well the function of B cell and T cell subtypes [254]. As a 
result, MeHg-treated animals are more susceptible to viruses and bacterial infections [255]. 
MeHg also induces the autoimmune response by producing antinucleolar antibodies [256] and 
anti- DNA antibodies [257].  
 
Paternal exposure to mercury in humans does not appear to cause infertility or malformations 
[258], but a study of pregnancy outcomes among the wives of 152 men occupationally exposed 
to Hg showed an increased incidence of spontaneous abortion [259]. At urinary Hg concentration 
levels exceeding 50 µg/L in male workers, the spontaneous abortion risk in their wives was 
doubled [259]. In animal tests, MeHg treatment caused abnormal sperm and a low conception 
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rate in monkeys [260]. In a mouse model, MeHg was shown to cause tubular atrophy of the 
testes [261].  
 
The developing kidney is more sensitive to inhaled than to organic mercury [262]. High mercury 
exposure results in mild transient proteinuria, gross proteinuria, hematuria, oliguria and acute 
renal failure. Kidney biopsy specimens from patients with nephrotic syndrome following 
exposure to metallic mercury demonstrated proximal tubular and glomerular changes, such as 
necrosis of the tubule epithelium, swollen granular protoplasm and nonstainable nuclei in the 
kidneys, partially due to mercury accumulation [263, 264]. In rodents, MeHg has been shown to 
cause renal fibrosis [265], increase renal weight, decrease renal enzymes [266, 267] and result in 
renal hypertrophy [268]. Microscopic examinations reveal cytoplasmic masses in proximal 
tubules [269], degeneration of proximal tubules and interstitial fibrosis [270].   
 
MeHg also affects other organ systems. It increases the risk for anemia and clotting disorders 
[271]. Furthermore, the cardiovascular system appears to be a target for MeHg toxicity in both 
human beings and animals, with adverse health effects including the following: 1) both elemental 
and organic forms of Hg alter blood-pressure regulation; 2) men with hair Hg concentration 
exceeding 2ppm have increased risk of acute myocardial infarction; and 3) prenatal exposure to 
MeHg is linked to heart-rate variability in children [252].    
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Risk Assessment  
The risk and toxicity of MeHg have been analyzed by three epidemiological studies since the 
EPA's derivation of an RfD in 1995 [272]. These longitudinal, developmental studies were 
conducted in the Seychelles Islands, the Faroe Islands and in New Zealand 
(http://www.epa.gov/iris/subst/0073.htm). The subjects of the Seychelles longitudinal 
prospective study were 779 mother–infant pairs from a fish-eating population [273-276]. Infants 
were followed from birth to 5.5 years of age and assessed at various ages on a number of 
standardized neuropsychological endpoints. The independent variable was maternal-hair mercury 
levels. The Faroe Islands study was a longitudinal study of about 900 mother–infant pairs [277]. 
The main independent variable was cord-blood mercury; maternal-hair mercury was also 
measured. Children were evaluated at 7 years of age, based on a variety of tasks designed to 
assess function in specific behavioral domains. The New Zealand study was a prospective case 
control study of 38 children born to women with hair mercury levels greater than 6 ppm during 
pregnancy matched with children whose mothers had lower hair mercury levels [278, 279]. At 6 
years of age, 237 children were assessed on a number of neuropsychological endpoints similar to 
those used in the Seychelles study [279]. The Seychelles study yielded scant evidence of 
impairment related to in utero MeHg exposure, whereas the other two studies found dose-related 
effects on a number of neuropsychological endpoints. However, in a 9-year follow-up study of 
643 children, the authors of the Seychelles study did not find an association between prenatal 
MeHg exposure and developmental outcomes [280]. An analysis by Davidson of the same 
population in a 10.7 year follow-up found a significant association between prenatal exposure to 
MeHg and impaired visuospatial ability [281]. Furthermore, a National Academy of Sciences 
(NAS) expert panel reviewed the studies and concluded that the weight of the evidence 
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supported adverse health effects due to MeHg exposure [272] and recommended that levels of 
mercury not exceed 5.0 µg/L in whole blood or 1.0 µg/g in hair, corresponding to a reference 
dose (RfD) of 0.1 µg/kg body weight/day.  
 
Various agencies have developed guidelines for “safe” exposure to MeHg, including the EPA 
[282], the U.S. Agency for Toxic Substances and Disease Registry [71], the U.S. Food and Drug 
Administration and the World Health Organization. These exposure levels range from 0.1 µg/kg 
body weight/day (EPA) to 0.47 µg/kg body weight/day [283]. The range of recommendations is 
due to varying safety margins, differing emphasis placed on various sources of data, the 
particular missions of the respective agencies and the unique population that each guideline is 
intended to protect. All guidelines, however, fall within the same order of magnitude. Although 
these guidelines may be used as screening tools in risk assessments to evaluate the “safety” of 
Hg exposures, they are not meant to be distinctive lines above which toxicity will definitely 
occur. However, as exposure levels increase in multiples of these guidelines, members of the 
public health community have become increasingly concerned that adverse health consequences 
may occur [282]. 
 
It needs to be emphasized that these levels of exposure to MeHg can be readily attained with 
only a few meals of fish per week, depending on the source and type of fish. In populations 
dependent on fish as their source of protein (e.g., in the Faroe Islands), increased hair Hg levels 
(up to 4.27 ppm) during pregnancy have been shown to be associated with impaired 
psychomotor test performance of children at 7 years of age [277]. Further, this type of diet led to 
an average cord-blood MeHg level of 22.9µg/L and was correlated with neurophysiological and 
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neuropsychological deficits. In a follow-up study in the Faroe Islands, it was reported similar 
correlations persisted in 14-year-old children [284]. In Japan, a strong association between the 
prevalence of mental retardation and Hg concentration in the umbilical cord was reported both in 
Minamata [285] and Niigata [286]. In another study from New Zealand [287] maternal hair Hg 
levels exceeding 6 ppm (range 5-20 ppm) correlated with a deficit in the Denver developmental 
screening test as well as a neurological screening test in children at 4 years of age. However, an 
epidemiological study in the province of Quebec, Canada [288] indicated no consistent 
relationship between maternal hair MeHg levels of 24 ppm during pregnancy and developmental 
outcomes in the female offspring. Also, in the Seychelles study [273, 287, 289] no adverse 
effects were detected at a maternal MeHg hair level of 6.8 ppm. The apparent differences in 
outcomes between the Faroe Islands and Seychelles studies are likely due to numerous factors, 
extensively reviewed by the National Academy of Science (NAS) [272]. The NAS emphasized 
that the weight of the evidence supported adverse health effects from MeHg [272] and 
recommended that levels of Hg not exceed 5.0 µg/L in whole blood or 1.0 µg/g  in hair, 
corresponding to a reference dose (RfD) of 0.1 µg/kg body weight/day.  
 
Treatment   
The first step of treatment is to remove patients from the source of exposure. Decontamination 
requires removal of clothes, flushing eyes and exposed mucosa with saline solution, and washing 
skin with soap and water. If mercury is swallowed, activated charcoal is used to limit further 
mercury absorption from GI system. Patients are given adequate fluids and electrolytes to 
expedite the excretion of mercury through urine. In the severe cases, dialysis could be used. 
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Immediate chelation therapy is the standard of care for patient showing any symptoms of severe 
mercury poisoning or the patient history suggesting a large total mercury load [290].  
 
Drug choice in chelation therapy depends on the form of mercury and patient age. In adult 
patients, acute inorganic mercury poisoning can be treated with Dimercaptosuccinic 
acid  (DMSA), 2,3-dimercapto-1-propanesulfonic acid (DMPS), D-penicillamine (DPCN) or 
dimercaprol (BAL). Of these, only DMSA is currently approved by the FDA for the treatment of 
children exposed to mercury. However, previous studies found no clear clinical benefit from 
DMSA treatment in mercury vapor poisoning [291]. DMSA given orally has fewer side effects 
and has been reported to be superior to BAL, DPCN and DMPS [292]. Glutathione and Alpha-
lipoic acid could also be used in mercury poisoning treatment, but they may increase mercury 
concentrations in the kidney and the brain, although the underlying mechanism is still unknown 
[293]. Notably, chelation therapy can be hazardous. Baxter [294] reported an incorrect form of 
EDTA used for chelation therapy caused cardiac arrest in a five-year-old autistic boy due to 
irreversible hypocalcemia.  
 
Concluding Remarks and Future Directions 
MeHg is a well-documented neurotoxicant. Studies in children suffering from tragic MeHg 
poisoning outbreaks in Japan and Iraq have revealed the pronounced susceptibility of the 
developing brain to MeHg. As a consequence, a plethora of studies have drawn attention to the 
consequences of prenatal exposure. Previous animal experiments also have shown similar 
neuromorphological and neurobehavioral alterations induced by MeHg after either acute or 
chronic exposure. Particular attention was directed to comparative toxicity assessments across 
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species and to the degree of concordance between human and animal data. In general, these 
studies have established that prenatal MeHg exposure in both humans and laboratory animals 
leads to diffuse brain damage including reduced brain size, damage to the cortex and basal 
ganglia, loss of cells, ventricular dilation, ectopic cells, disorganized brain layers and gliosis. The 
main difference between the human and the monkey in neuropathology is the relative 
insensitivity of the monkey’s cerebellum to MeHg, which represents a major target in humans. 
Clinical symptoms of prenatal MeHg exposure include blindness, auditory defects, 
somatosensory impairment, difficulty in learning and delays in social development and in the 
attainment of cognitive milestones.  
 
Guidelines for exposure to MeHg range from 0.1ug/kg body weight/day (EPA) to 0.47ug/kg 
body weight/day (WHO). The differences in the guidelines between various regulatory agencies 
are largely due to the uncertainties intrinsic to human epidemiological studies, including 
unmeasured confounders and effect modifiers, which could compromise the exposure outcomes. 
Thus, additional research addressing interspecies comparisons is necessary to determine a more 
specific standard for critical dose levels of MeHg. An accurate interspecies comparison should 
take several key factors into account, including the species-related differences in the kinetics of 
MeHg distribution and its concentration in target organs. Basu and colleagues studied the 
inhibitory effects of MeHg on the mACh receptor in the cerebral cortex and further cross-
compared the species sensitivity between the human, rat, mouse, mink and river otter. Species 
sensitivities, irrespective of Hg type and brain region, can be ranked from most to least sensitive 
as follows: river otter>rat>mink>mouse>humans [295]. Thus, a well-designed comparative study 
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could provide data on interspecies differences and a framework for interpreting results generated 
from human, murine and wildlife studies.  
 
As a potent environmental pollutant, MeHg reacts with DNA, RNA and proteins. Studies on the 
potential for toxicogenomic effects of MeHg are sparse, and future studies should focus on the 
identification of single nucleotide polymorphisms (SNPs) in various genes that will elicit novel 
information regarding the role of gene and environment interactions and a particular individual’s 
susceptibility to MeHg. Due to the considerable disadvantages inherent in both human 
epidemiological studies and animal experiments, toxicologists face the major challenge of 
developing and validating other, more targeted and controlled model systems. For example, 
using Caenorhabditis elegans (C. elegans) as the model system in toxicological research is very 
promising due to this species’ simple and well-defined nervous system, its ready visualization 
through the use of green fluorescent protein (GFP) and its rapid life cycle [296]. Further 
improving the C. elegans model and developing in vitro models will prove of particular import 
because future toxicological studies will be greatly expanded to cover a much wider range of 
environments and numbers of species. Additionally, the development of high throughput 
methods in proteomics, genomics and bioinformatics will lead to better understanding the 
developmental toxicity of MeHg by the accumulation of vast amounts of valuable toxicological 
information.  
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